DHCR24 inhibitory compounds
By developing selective, powerful and non-toxic DHCR24 inhibitors, the problem of poor effectiveness of DHCR24 inhibitors in the prior art has been solved, and effective treatment and prevention of various diseases has been achieved, especially in improving endogenous properties Chain sterol levels and intracerebral effects.
Patent Information
- Application Number
- CN202380031564.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-07
- Filing Date
- 2023-03-07
- Publication Date
- 2024-11-15
AI Technical Summary
Existing DHCR24 inhibitors lack selectivity, potency and non-toxicity, making it difficult to effectively treat a variety of diseases mediated by Δ24-dehydrocholesterol reductase, such as non-alcoholic steatohepatitis and atherosclerotic cardiovascular disease. and multiple sclerosis.
A new class of compounds, compounds of formula (10), selective, potent and non-toxic DHCR24 inhibitors, has increased endogenous chain sterol levels through specific fused ring systems and group structures, suitable for Clinical use and has improved water solubility and stability.
This compound is able to effectively inhibit DHCR24 and increase endogenous chain sterol levels. It is used to treat or prevent DHCR24-mediated conditions and shows potential in clinical applications, especially in the brain and not blocked by the blood-brain barrier.
Smart Images

Figure CN118973585A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to compounds suitable for the inhibition of Δ24-dehydrocholesterol reductase (DHCR24), in particular the selective inhibition of DHCR24. These compounds are useful as drugs, in particular as agents for the treatment and / or prevention of DHCR24-mediated disorders such as non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD) or multiple sclerosis (MS). Background Art
[0002] Cholesterol is known to be an important storage lipid and cellular building block. Over the past decade, the understanding of the biological roles of cholesterol biosynthesis and its biosynthetic precursors has changed dramatically. Cholesterol biosynthesis is associated with a variety of different diseases, and research has focused on the biological functions of key intermediates and enzymes involved in cholesterol biosynthesis.
[0003] Cholesterol biosynthesis is divided into the anterior mevalonate pathway and the posterior squalene pathway, the latter also called distal cholesterol biosynthesis. De novo cholesterol biosynthesis is accomplished by eleven enzymes in the mevalonate pathway (starting from acetyl-CoA) and nine enzymes involved in distal cholesterol biosynthesis. The latter is further divided into the Bloch pathway and the Kandutsch-Russell pathway (see Figure 1 ).
[0004] The Bloch pathway contains a Δ24-unsaturated intermediate and is interconnected with the Kandutsch-Russel branch through the action of the enzyme DHCR24. DHCR24 is a membrane-bound enzyme that catalyzes the anaerobic reduction of the Δ24-double bond in the side chain of the precursor sterol (see Figure 1 and Figure 2 ). It has been shown that the two pathways are not strictly separated, but rather tissue- and cell-type-specific interactions of the two pathways are observed, with a preference for the Kandutsch-Russel pathway. The major substrate of DHCR24 is lanosterol (4,4,14-trimethylcholesta-8,24-dien-3β-ol, see Figure 1 (1)) and yeast sterol (cholesta-8,24-diene-3β-ol, see Figure 1 (11)), and cholesta-7,24-diene-3β-ol (see Figure 1 (12) in ).
[0005] Reduction of the Δ24 double bond can occur in the final step of the Bloch pathway, which converts the chain sterol (cholesta-5,24-dien-3β-ol, see Figure 1 and 2 (14)) into cholesterol (see Figure 1 and 2 DHCR24 does not require cofactors other than NADPH. Reduction of the Δ24 double bond occurs in two steps by initial introduction of a proton at C24 to generate a cationic high energy intermediate (HEI) at C25, followed by nucleophilic addition of NADPH to the hydride (see Figure 2 Dysfunction or inhibition of DHCR24 results in the biosynthesis of cholesterol in mammals proceeding via the Bloch pathway, ultimately leading to the accumulation of inter-chain sterols.
[0006] Desmosterolosis (MIM 602398) is a rare genetic disorder affecting the DHCR24 gene. Desmosterolosis is a very rare disease with only a few clinically described cases. Desmosterolosis is associated with severe abnormalities, such as microcephaly with corpus callosum dysgenesis, convulsions, nystagmus, strabismus and micrognathia. It has been found that mild accumulation of desmosterol has no effect on vitality, especially when combined with a cholesterol-rich diet, as exemplified by heterozygous carriers of DHCR24 mutations. Therefore, moderate accumulation of desmosterol in vivo by inhibiting DHCR24 has been shown to be non-toxic. Carriers of DHCR24 mutations on a single allele have been shown to have normal cholesterol levels, in which the plasma concentration of desmosterol has only increased by 1.5 times.
[0007] Biologically, the roles of DHCR24 are diverse, and inhibition of DHCR24 is a promising drug target for the treatment of a variety of diseases. Therefore, there is a need for selective, potent and non-toxic DHCR24 inhibitors that could be useful in many therapeutic areas. Summary of the invention
[0008] In the first aspect, the present invention provides a compound of formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof. The compound of formula (10) is:
[0009]
[0010] in:
[0011] G is a fused ring system selected from the following:
[0012]
[0013] B is selected from:
[0014]
[0015] R 1 Selected from hydrogen, -C(=O)R 6 and C 1-6 alkyl;
[0016] R 2 Selected from hydrogen and C 1-6 alkyl;
[0017] R 3 A group selected from the group represented by formula (2), -[C(R 7 )2] n -X, -CH=CR 6 R 7 , -CR 7 =NN(R 6 )2, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0018]
[0019] n is an integer from 1 to 6;
[0020] W is selected from O and NR 6 ;
[0021] Y is selected from hydrogen and C2 alkenyl, wherein C2 alkenyl is optionally substituted with one or more halogens;
[0022] X is selected from halogen, -OH, -SH, -OZ, -SZ, -SSZ, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0023] Each R 4 are independently selected from hydrogen and C 1-6 alkyl;
[0024] R 5 Selected from hydrogen and C 1-6 alkyl;
[0025] Each R 6 are independently selected from hydrogen and C 1-6alkyl;
[0026] Each R 7 Independently selected from H, C 1-6 Alkyl and C 2-6 Alkenyl, where C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens;
[0027] Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0028] The compound of formula (10) is not one of the following:
[0029]
[0030]
[0031] The dotted line in formula (10) indicates the position of the fused ring system represented by G. Similarly, the dotted line in one structure of G represents the position of the group represented by B.
[0032] The inventors unexpectedly identified a class of compounds that inhibit DHCR24. These compounds are selective, potent and non-toxic inhibitors of DHCR24. In view of the various biological effects of DHCR24, the selectivity of the compounds for inhibiting DHCR24 is important for their pharmaceutical or clinical use in treating or preventing DHCR24-mediated conditions. The inhibition of DHCR24 by the compounds of the present invention increases endogenous chain sterol levels.
[0033] Compared to other inhibitors of DHCR24, the compounds identified by the present invention have advantageous properties when formulating drug products for clinical use (e.g., Lipinski's rule can be applied). Therefore, the compounds have improved water solubility and better stability. It is expected that these compounds are also suitable for direct oral administration.
[0034] Another aspect of the present invention provides a compound of formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for use in treating or preventing a DHCR24-mediated disorder. This aspect of the present invention also provides a method for treating or preventing a DHCR24-mediated disorder. The method comprises administering a compound of formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, to a subject.
[0035] In a second aspect, the present invention provides a compound of formula (1), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for use in treating or preventing a DHCR24-mediated disorder.
[0036] The second aspect of the present invention also provides a method for treating or preventing a DHCR24-mediated disorder, which comprises administering to a subject a compound of formula (1), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
[0037] In the second aspect of the present invention, the compound of formula (1) is:
[0038]
[0039] in:
[0040] G is a fused ring system selected from the following:
[0041]
[0042] B is selected from:
[0043]
[0044] R 1 Selected from hydrogen, -C(=O)R 6 and C 1-6 alkyl;
[0045] R 2 Selected from hydrogen and C 1-6 alkyl;
[0046] R 3 A group selected from the group represented by formula (2), -[C(R 7 )2] n -X, -C(=O)NHOR 8 、-C(=O)OR 8 , -CR 7 =NN(R 6 )2, -CH=CR 6 R 7 , C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0047]
[0048] n is an integer from 1 to 6;
[0049] W is selected from O, S and NR 6 ;
[0050] Y is selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, amino-C 1-6 Alkyl, (mono-C 1-6 Alkylamino)C 1-6 Alkyl and (di-C 1-6 Alkylamino)C 1-6 Alkyl, where C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens;
[0051] X is selected from halogen, -OH, -SH, -N(R 6 )2, -OZ, -SZ, -SSZ, -C(=O)R 7 , C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0052] Each R 4 are independently selected from hydrogen and C 1-6 alkyl;
[0053] R 5 Selected from hydrogen and C 1-6 alkyl;
[0054] Each R 6 are independently selected from hydrogen and C 1-6 alkyl;
[0055] Each R 7 Independently selected from H, C 1-6 Alkyl and C 2-6 Alkenyl, where C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens;
[0056] R 8 Selected from C 1-6 Alkyl and C 2-6 alkenyl, and
[0057] Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0058] The dotted line in formula (1) indicates the position of the fused ring system represented by G. Similarly, the dotted line in one structure of G represents the position of the group represented by B.
[0059] The experimental data presented herein, particularly the in vivo data, provide compelling evidence that the compounds may be clinically useful for treating or preventing DHCR24-mediated disorders. These compounds may produce effects within the brain (eg, they are not blocked by the blood-brain barrier).
[0060] Another aspect of the present invention is to provide a pharmaceutical composition comprising a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable excipient.
[0061] In another aspect, the present invention provides a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for use in therapy and / or as a medicament.
[0062] In another aspect, the present invention provides the use of a compound of formula (1) or formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in the preparation of a medicament for treating or preventing a DHCR24-mediated disorder.
[0063] Another aspect of the present invention provides a method for inhibiting DHCR24 activity in vivo or in vitro. The in vivo or in vitro method comprises contacting a cell with a compound of formula (1) or (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein. Alternatively, the in vivo method may comprise administering a compound of formula (1) or (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein to a subject.
[0064] In another aspect, the present invention provides a combination comprising a compound of formula (1) or formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and one or more additional therapeutic agents.
[0065] Preferred, suitable and optional features of any particular aspect of the invention are also preferred, suitable and optional features of any other aspect. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] The present invention is further described below with reference to the accompanying drawings.
[0067] Figure 1 is a scheme showing the enzymatic steps of distal cholesterol biosynthesis. Participating enzymes: (A) sterol C24-reductase (Δ24-dehydrocholesterol reductase (DHCR24)), (B) sterol C14 demethylase (CYP51), (C) sterol C14-reductase (Δ14-dihydrocholesterol reductase (DHCR14)), (D) sterol C4-methyloxidase, (E) sterol C3-dehydrogenase, (F) sterol C3-ketoreductase, (G) sterol C8-isomerase (emapomil binding protein (emapomil binding protein, EBP)), (H) sterol C5-desaturase (SC5D)), (I) sterol C7-reductase (Δ7-dehydrocholesterol reductase (DHCR7)). Intermediates: (1) 4,4,14-trimethylcholesta-8,24-dien-3β-ol (lanosterol), (2) 4,4,14-trimethylcholesta-8-en-3β-ol (dihydrolanosterol), (3) 4,4-dimethylcholesta-8,14-dien-3β-ol, (4) 4,4-dimethylcholesta-8-en-3β-ol, (5)cholesta-8-en-3β-ol (zymosterol), (6)cholesta-7-en-3β-ol (cholesta-enol), (7)cholesta-5,7-dien-3β-ol (7-dehydrocholesta-1), (8)cholesta-5-en-3β-ol (cholesterol), (9) 4,4-dimethylcholesta-8,14,24-trien-3β-ol (follicular fluid meiosis activating sterol activating sterol, FF-MAS)), (10) 4,4-dimethylcholester-8,24-dien-3β-ol (testis meiosis activating sterol (testismeiosis activating sterol, T-MAS)), (11) cholesta-8,24-dien-3β-ol (zymosterol), (12) cholesta-7,24-dien-3β-ol, (13) cholesta-5,7,24-trien-3β-ol (7-dehydrocholesterol), (14) cholesta-5,24-dien-3β-ol (chain sterol).
[0068] Figure 2 is a reaction scheme showing a hypothesized mechanism of the DHCR24 enzyme reaction.
[0069] Figure 3 is a series of histograms showing the results of multiple in vivo experiments using Example 11 (SH42).
[0070] Figure 4 and Figure 5Results of in vivo experiments are shown in which levels of inter-chain sterols were measured in the brain of mice after treatment with Example 11 or Example 33. DETAILED DESCRIPTION
[0071] definition
[0072] The compounds and intermediates described herein may be named according to the IUPAC (International Union for Pure and Applied Chemistry) or CAS (Chemical Abstracts Service) nomenclature system. It should be understood that, unless expressly stated to the contrary, the terms "compound of formula (1)" and "compound of formula (10)" refer to and include any and all compounds described by and / or with reference to formula (1) or formula (10), respectively. It should also be understood that these terms encompass all stereoisomers (i.e., cis and trans isomers) of such compounds and all salts thereof, as well as optical isomers (i.e., R and S enantiomers and diastereomers), in substantially pure form and / or in any mixture of the foregoing in any ratio. This understanding extends to pharmaceutical compositions and methods of treatment using or containing one or more compounds of formula (1) or formula (10), whether by themselves or in combination with another agent.
[0073] The various hydrocarbon-containing moieties provided herein may be described using prefixes designating the minimum and maximum number of carbon atoms in the moiety, e.g., "C a-b " or "C a -C b For example, C a-b Alkyl represents an alkyl moiety having an integer "a" to an integer "b" (including the end values) of carbon atoms. Certain moieties may also be described according to the minimum and maximum number of members, with or without specific reference to a particular atom or overall structure. For example, the term "a- to b-membered ring" or "having a to b members" refers to a moiety having an integer "a" to an integer "b" (including the end values) of atoms.
[0074] When the term "about" is used herein in connection with a measurable value (eg, such as an amount or a time period, etc.), it is meant to cover reasonable variations in that value, for example, allowing for experimental error in the measurement of the value.
[0075] The term "alkyl" or "alkyl group" when used herein by itself or in combination with another or more terms refers to a branched or unbranched saturated hydrocarbon chain. Unless otherwise indicated, an alkyl group typically contains 1 to 6 carbon atoms (e.g., 1 to 4 carbon atoms or 1 to 3 carbon atoms) and may be substituted or unsubstituted. Unless the context otherwise indicates, an alkyl group is unsubstituted. Some representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, isopropyl, tert-butyl, isobutyl, etc.
[0076] The term "alkenyl" or "alkenyl group" when used herein by itself or in combination with another or more terms refers to a branched or unbranched hydrocarbon chain containing at least one double bond. Unless otherwise indicated, alkenyl groups typically contain 2 to 6 carbon atoms (e.g., 2 to 4 carbon atoms) and may be substituted or unsubstituted. Unless the context otherwise indicates, alkenyl groups are unsubstituted. Some representative examples include, but are not limited to, vinyl, 3-butene-1-yl, 2-vinylbutyl, and 3-hexene-1-yl.
[0077] The term "amino-alkyl" or "amino-alkyl group" as used herein by itself or in combination with another or more terms refers to an alkyl group in which one hydrogen atom is replaced by a primary amino group (-NH2). 1-6 Alkyl" and "amino-C 1-6 "Alkyl group" refers to an amino-alkyl group wherein the alkyl group contains 1 to 6 carbon atoms. Some representative examples include, but are not limited to, -CH2NH2, CH2CH2NH2, and -CH(CH3)NH2. Amino-alkyl groups can be substituted or unsubstituted. Unless the context indicates otherwise, amino-alkyl groups are unsubstituted.
[0078] The term "(mono-alkylamino)-alkyl" or "(mono-alkylamino)-alkyl group" as used herein by itself or in combination with another term or terms refers to an alkyl group in which one hydrogen atom is preferably replaced by an amino group (-NHR'), wherein the amino group has a single alkyl substituent (e.g., R'). The expression "(mono-C 1-6 Alkylamino)C 1-6 The term "mono-C 1-6 "Alkylamino" refers to a single alkyl group on an amino group containing 1 to 6 carbon atoms. Some representative examples include, but are not limited to, -CH2NH(CH3), -CH2NH(CH2CH3), and -CH2CH2NH(CH3). A (mono-alkylamino)-alkyl group can be substituted or unsubstituted. Unless the context indicates otherwise, a (mono-alkylamino)-alkyl group is unsubstituted.
[0079] The term "(di-alkylamino)-alkyl" or "(di-alkylamino)-alkyl group" as used herein by itself or in combination with another or more terms refers to an alkyl group in which one hydrogen atom is preferably replaced by an amino group (-NR'2), wherein the amino group has two alkyl substituents (e.g., each represented by R'). The expression "(di-C 1-6 Alkylamino)C 1-6 The term "di-C 1-6 "Alkylamino" refers to two alkyl groups on an amino group, wherein each alkyl group independently contains 1 to 6 carbon atoms. Some representative examples include, but are not limited to, -CH2N(CH3)2, -CH2N(CH2CH3)(CH3), and -CH2CH2N(CH3)2. A (di-alkylamino)-alkyl group can be substituted or unsubstituted. Unless the context indicates otherwise, a (di-alkylamino)-alkyl group is unsubstituted.
[0080] The terms "alkoxy" and "alkoxy group" when used herein by themselves or in combination with another or more terms refer to an alkyl-oxy group, i.e., an alkyl group in which one hydrogen atom is replaced by an oxy group (-O-). Some representative examples include, but are not limited to, OCH3, OCH2CH3, and OCH(CH3)2. Alkoxy groups can be substituted or unsubstituted. Unless the context indicates otherwise, alkoxy groups are unsubstituted.
[0081] The term "aromatic" when used herein by itself or in combination with another or more terms refers to monocyclic and polycyclic ring systems containing 4n+2π electrons, where n is an integer. Aromatic should be understood to refer to and include ring systems containing only carbon atoms (i.e., "aryl") as well as ring systems containing at least one heteroatom selected from N, O or S (i.e., "heteroaromatic" or "heteroaryl"). Aromatic ring systems can be substituted or unsubstituted.
[0082] The term "non-aromatic" when used herein by itself or in combination with another or more terms refers to a monocyclic or polycyclic ring system that is saturated or has at least one double bond that is not part of an extended conjugated π system. As used herein, non-aromatic refers to and includes ring systems containing only carbon atoms as well as ring systems containing at least one heteroatom selected from N, O or S. Non-aromatic ring systems may be substituted or unsubstituted.
[0083] The term "aryl" or "aryl group" when used herein by itself or in combination with another or more terms refers to phenyl and a 6- to 10-membered bicyclic hydrocarbon ring system, including a fused ring system, in which at least one ring is aromatic. The aryl group may be substituted or unsubstituted. Unless otherwise indicated, the aryl group may contain 6 ring atoms (i.e., phenyl) or a ring system containing 6 to 10 atoms (e.g., 9 or 10 ring atoms). Some representative examples include, but are not limited to, naphthyl, indanyl, and 1,2,3,4-tetrahydronaphthyl. Preferably, the aryl group is phenyl or naphthyl, more preferably phenyl. The aryl group may be substituted or unsubstituted. Unless otherwise indicated by the context, the aryl group is unsubstituted.
[0084] The terms "halo," "halo," "halogen," and "halogen group," when used herein, by themselves or in combination with another or more terms, include fluorine (—F), chlorine (—Cl), bromine (—Br), or iodine (—I) atoms and substituents.
[0085] The term "heteroaryl" or "heteroaryl group" as used herein, by itself or in combination with another or more terms, refers to:
[0086] (a) 5- and 6-membered monocyclic aromatic rings which, in addition to carbon atoms, contain at least one heteroatom, such as nitrogen, oxygen or sulfur; and
[0087] (b) a 7- to 10-membered bicyclic ring which, in addition to carbon atoms, contains at least one heteroatom, such as nitrogen, oxygen or sulfur;
[0088] and wherein at least one ring is an aromatic ring. In some cases, the heteroaryl group may contain two or more heteroatoms, which may be the same or different. The heteroaryl group may be substituted or unsubstituted and may be fused. In some cases, the heteroaryl group may contain 5, 6, or 8 to 10 ring atoms. In other cases, the heteroaryl group may contain 5 to 10 ring atoms, such as 5, 6, 9 or 10 ring atoms. Some representative examples include, but are not limited to, 2,3-dihydrobenzofuranyl, 1,2-dihydroquinolyl, 3,4-dihydroisoquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3-4-tetrahydroquinolyl, benzofuran ... oxazinyl, benzothiazinyl, chromanyl, furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl, isocyanyl Azolyl, isothiazolyl, Oxazolyl, oxazolyl, pyridinyl (e.g., 2-, 3-, or 4-pyridinyl), pyrimidinyl (e.g., 2-, 4-, or 5-pyrimidinyl), pyrazolyl, pyrrolyl (e.g., 2 or 3-pyrrolyl), pyrazinyl, pyridazinyl (e.g., 3- or 4-pyridazinyl, 2-pyrazinyl), thienyl (e.g., 2-thienyl, 3-thienyl), tetrazolyl, thiazolyl, thiadiazolyl, triazinyl, triazolyl, pyridin-2-yl, pyridin-4-yl, pyrimidin-2-yl, pyridazin-4-yl, pyrazin-2-yl, naphthyridinyl, pteridinyl, phthalazinyl, purinyl, benzimidazolyl, benzofuranyl, benzofurazanyl, 2H-1-benzopyranyl, benzothiadiazinyl, benzothiazinyl, benzothiazolyl, benzothienyl, benzo Preferably, the heteroaryl group is a 5- or 6-membered heteroaryl ring containing one, two or three heteroatoms selected from N, O or S. Unless the context indicates otherwise, the heteroaryl group is unsubstituted.
[0089] The term "heterocycloalkyl" or "heterocycloalkyl group" when used by itself or in combination with another or more terms herein, refers to a 3- to 10-membered monocyclic or bicyclic non-aromatic ring system, which contains at least one heteroatom, such as nitrogen, oxygen, sulfur or phosphorus, in addition to carbon atoms. The heterocycloalkyl group can be fully saturated or contain unsaturated moieties and can be a bridged ring, a spiro ring and / or a fused ring system. In some cases, the heterocycloalkyl group can contain at least two or more heteroatoms, which can be the same or different. The heterocycloalkyl group can be substituted or unsubstituted. In some cases, the heterocycloalkyl group can contain 3 to 10 ring atoms or 3 to 7 ring atoms, or 5 to 7 ring atoms, such as 5 ring atoms, 6 ring atoms or 7 ring atoms. Some representative examples include, but are not limited to, tetrahydrofuranyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, isoindolinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, thiomorpholinyl-5-oxide, thiomorpholinyl-S,S-dioxide, pyrrolidinyl, tetrahydropyranyl, piperidinyl, tetrahydrothiophenyl, homopiperidinyl, homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuranyl, dihydropyranyl, azetidinyl, azepanyl, diazepanyl (e.g., 1,4-diazepanyl), oxazepanyl (e.g., 1,4-oxazepanyl), thiazepanyl (e.g., 1,4-thiazepanyl), tetrahydrothienyl-5-oxo- 2- oxa-5-azabicyclo[2.2.1]heptyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diaza-bicyclo[2.2.1]heptyl, 3,8-diaza-bicyclo[3.2.1]octyl, 3,9-diaza-bicyclo[4.2.1]nonyl and 2,6-diaza-bicyclo[3.2.2]nonyl. Preferably, the heterocycloalkyl group as defined herein is a monocyclic, bicyclic or spirocyclic group containing one, two or three heteroatoms selected from N, O or S. Unless the context indicates otherwise, the heterocycloalkyl group is unsubstituted.
[0090] The term "pharmaceutically acceptable", as used herein, by itself or in combination with another term or terms, refers to a material that is generally chemically and / or physically compatible with the other ingredients (e.g., such as a reference formulation), and / or generally physiologically compatible with a recipient thereof (e.g., such as a subject).
[0091]
[00136] The term "pharmaceutical composition," as used herein, by itself or in combination with another term or terms, refers to a composition that is useful for treating a disease, condition, or disorder in a subject, including a human.
[0092] The terms "subject" and "patient" as used herein by themselves or in combination with another term or terms, appropriately refer to mammals, particularly humans.
[0093] The term "substituted" when used herein by itself or in combination with another or more terms, means that a hydrogen atom on a molecule has been replaced by a different atom or group of atoms, and the atom or group of atoms replacing the hydrogen atom is the "substituent". It should be understood that the term "substituent" and variations thereof, "moiety" and variations thereof, "group" and variations thereof refer to a substituent.
[0094] The terms "therapeutic" and "therapeutically effective amount" when used herein by themselves or in combination with another or more terms refer to an amount of a compound, composition, or drug that (a) inhibits or causes improvement in a particular disease, condition, or disorder; (b) attenuates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder; (c) or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. It should be understood that the terms "therapeutic" and "therapeutically effective" encompass any of the aforementioned effects (a) to (c), alone or in combination with any of the other (a) to (c). For example, it should be understood that in humans or other mammals, a therapeutically effective amount can be determined experimentally in a laboratory or clinical setting, or a therapeutically effective amount can be the amount required by the guidelines of the United States Food and Drug Administration (FDA) or equivalent foreign regulatory agencies for the particular disease and subject being treated. It should be understood that the determination of appropriate dosage forms, dosage amounts, and routes of administration are within the ordinary skill level of the pharmaceutical and medical arts.
[0095] The term "treatment" and its variations, whether used by itself or in combination with another or more terms herein, refer to and include preventive, ameliorative, palliative and curative uses and results. In some embodiments, the term "treatment" and its variations refer to curative uses and results, as well as uses and results that alleviate or reduce the severity of a particular condition, feature, symptom, disorder or disease described herein. For example, treatment may include the alleviation of several symptoms of a condition or disorder, or the complete eradication of the condition or disorder. It should be understood that the term "preventive" as used herein is not absolute, but refers to uses and results in which the administration of a compound or composition alleviates the likelihood or severity of a condition, symptom or disease state, and / or delays the onset of a condition, symptom or disease state for a period of time.
[0096] As used herein, "therapeutically active agent", whether used alone or in combination with another or more terms, refers to any compound (i.e., drug) that has been found to be useful for treating a disease, disorder, or condition and is not described by formula (1) or formula (10). It should be understood that a therapeutically active agent may not be approved by the FDA or an equivalent foreign regulatory agency.
[0097] "Therapeutically effective amount" means the amount of a compound that, when administered to a subject or patient for treating a disease, is sufficient to effect such treatment of the disease."Therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject or patient to be treated.
[0098] As used herein, the term "DHCR24-mediated condition" means any disease, disorder or other pathological condition in which DHCR24 and / or chain sterols (preferably DCHR24) are known to play a role. In particular, the term "DHCR24-mediated condition" includes any disease, disorder or other pathological condition that can be treated and / or prevented by inhibiting DHCR24. Inhibition of DHCR24 increases chain sterols, which activate liver X receptors, particularly liver X receptor alpha (LXRα). Therefore, in some embodiments, the present disclosure relates to treating one or more diseases in which DHCR24 is known to play a role or reducing the severity of one or more diseases in which DHCR24 is known to play a role.
[0099] Description of the invention
[0100] In general, the present invention relates to compounds of formula (1) or compounds of formula (10).
[0101]
[0102] In formula (1) or formula (10), G is a fused ring system selected from the following:
[0103]
[0104] When G in formula (1) or formula (10) is a condensed ring system represented by (G1), the compound can be represented by formula (2-G1) or formula (20-G1), respectively.
[0105]
[0106] When G in formula (1) or formula (10) is a condensed ring system represented by (G2), the compound can be represented by formula (2-G2) or formula (20-G2), respectively.
[0107]
[0108] When G in formula (1) or formula (10) is a condensed ring system represented by (G3), the compound can be represented by formula (2-G3) or formula (20-G3), respectively.
[0109]
[0110] When G is a fused ring system represented by (G1), then B is selected from:
[0111]
[0112] When B is represented by (B1) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B1) or formula (20-B1), respectively.
[0113]
[0114] When B is represented by (B2) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B2) or formula (20-B2), respectively.
[0115]
[0116] When B is represented by (B3) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B3) or formula (20-B3), respectively.
[0117]
[0118] When B is represented by (B4) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B4) or formula (20-B4), respectively.
[0119]
[0120] When B is represented by (B5) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B5) or formula (20-B5), respectively.
[0121]
[0122] When B is represented by (B6) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B6) or formula (20-B6), respectively.
[0123]
[0124] When B is represented by (B7) and the compound is represented by formula (2-G1) or formula (20-G1), the compound can be represented by formula (2-B3) or formula (20-B3), respectively.
[0125]
[0126] In the compound of formula (1), the compound of formula (10), or any of the above formulae, R 3 It can be expressed by formula (2).
[0127]
[0128] When R 3 When represented by formula (2), the compound of formula (1) or formula (10) can be represented by formula (1-R3) or formula (10-R3), respectively.
[0129]
[0130] The present invention will now be further described by the following numbered paragraphs.
[0131] In a first aspect, the present invention provides a compound of formula (10), or a salt, solvate, hydrate or prodrug thereof, as defined herein above and below. The salt is preferably a pharmaceutically acceptable salt.
[0132] 1. The compound of formula (10) is:
[0133]
[0134] in:
[0135] G is a fused ring system selected from the following:
[0136]
[0137] B is selected from:
[0138]
[0139] R 1 is selected from hydrogen and -C(=O)R 6 ;
[0140] R 2 Selected from hydrogen and C 1-6 alkyl;
[0141] R 3 A group selected from the group represented by formula (2), -[C(R 7 )2] n -X, -CH=CR 6 R 7 , -CR 7 =NN(R 6 )2, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0142]
[0143] n is an integer from 1 to 6;
[0144] W is selected from O and NR 6 ;
[0145] Y is selected from hydrogen and C2 alkenyl, wherein C2 alkenyl is optionally substituted with one or more halogens;
[0146] X is selected from halogen, -OH, -SH, -OZ, -SZ, -SSZ, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0147] Each R 4 are independently selected from hydrogen and C 1-6 alkyl;
[0148] R 5 Selected from hydrogen and C 1-6 alkyl;
[0149] Each R 6 are independently selected from hydrogen and C 1-6 alkyl;
[0150] Each R 7 Independently selected from H, C 1-6 Alkyl and C 2-6 Alkenyl, where C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens;
[0151] Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0152] The prodrug is typically an ester, amide, hydrazone or disulfide of a compound of formula (10).
[0153] 2. The compound according to paragraph 1, wherein:
[0154] R 3 A group selected from the group represented by formula (2), -[C(R 7 )2] n -X and -CH=CR 6 R 7 ; and X is selected from halogen and -OH.
[0155] 3. The compound according to paragraph 1 or paragraph 2, which is represented by formula (10a):
[0156]
[0157] 4. The compound according to paragraph 1 or paragraph 2, which is represented by formula (10b):
[0158]
[0159] 5. The compound according to paragraph 1 or paragraph 2, which is represented by formula (10p):
[0160]
[0161] 6. The compound according to paragraph 1 or paragraph 2, which is represented by formula (10q):
[0162]
[0163] 7. The compound according to any one of paragraphs 1 to 3 or 5, which is represented by formula (10ap):
[0164]
[0165] 8. The compound according to any one of paragraphs 1 to 3 or 6, which is represented by formula (10aq):
[0166]
[0167] 9. The compound according to any one of paragraphs 1, 2, 4 or 5, which is represented by the formula (10bp):
[0168]
[0169] 10. The compound according to any one of paragraphs 1, 2, 4 or 6, which is represented by formula (10bq):
[0170]
[0171] 11. A compound according to any one of paragraphs 1 to 10, wherein R 1 It's hydrogen.
[0172] 12. A compound according to any one of paragraphs 1 to 10, wherein R 1 Yes-C(=O)R 6 .
[0173] 13. A compound according to any one of paragraphs 1 to 12, wherein when R 1 Yes-C(=O)R 6When R 6 It is C 1-6 Alkyl (such as R 1 Yes -C(=O)-C 1-6 alkyl).
[0174] 14. The compound according to paragraph 13, wherein R 6 is methyl or ethyl (e.g. R 1 is -C(=O)Me or -C(=O)Et).
[0175] 15. The compound according to paragraph 14, wherein R 6 is a methyl group (e.g. R 1 is -C(=O)-Me).
[0176] 16. A compound according to any one of paragraphs 1 to 15, wherein G is:
[0177]
[0178] 17. A compound according to paragraph 16, wherein G is:
[0179]
[0180] 18. A compound according to any one of paragraphs 1 to 17, wherein R 5 is selected from hydrogen, methyl and ethyl.
[0181] 19. The compound according to paragraph 18, wherein R 5 is selected from hydrogen and methyl.
[0182] 20. A compound according to any one of paragraphs 1 to 19, wherein R 5 It's hydrogen.
[0183] 21. A compound according to any one of paragraphs 1 to 19, wherein R 5 It's methyl.
[0184] 22. A compound according to any one of paragraphs 1 to 21, wherein each R 4 are independently selected from hydrogen, methyl and ethyl.
[0185] 23. A compound according to any one of paragraphs 1 to 22, wherein each R 4 are independently selected from hydrogen and methyl.
[0186] 24. A compound according to any one of paragraphs 1 to 23, wherein at least one R 4 It's hydrogen.
[0187] 25. A compound according to any one of paragraphs 1 to 24, wherein at least one R 4 It's methyl.
[0188] 26. A compound according to any one of paragraphs 1 to 24, wherein two R 4 It's all hydrogen.
[0189] 27. A compound according to any one of paragraphs 1 to 23, wherein two R 4 They are all methyl.
[0190] 28. A compound according to any one of paragraphs 1 to 27, wherein B is selected from:
[0191]
[0192] 29. A compound according to any one of paragraphs 1 to 28, wherein B is:
[0193]
[0194] 30. A compound according to any one of paragraphs 1 to 28, wherein B is:
[0195]
[0196] 31. A compound according to any one of paragraphs 1 to 30, wherein R 2 It's hydrogen.
[0197] 32. A compound according to any one of paragraphs 1 to 31, wherein R 3 is a group represented by formula (2):
[0198]
[0199] 33. A compound according to any one of paragraphs 1 to 32, wherein when R 3 When it is a group represented by formula (2), each R 6 are independently selected from hydrogen, methyl and ethyl.
[0200] 34. A compound according to any one of paragraphs 1 to 33, wherein when R 3 When it is a group represented by formula (2), at least one R 6 It's hydrogen.
[0201] 35. A compound according to any one of paragraphs 1 to 34, wherein R 3 is a group represented by formula (2a):
[0202]
[0203] 36. A compound according to any one of paragraphs 1 to 35, wherein when R 3 is a group represented by formula (2) or formula (2a) and when W is NR 6 When R 6 W is selected from hydrogen, methyl and ethyl (eg W is selected from NH, NMe and NEt).
[0204] 37. The compound according to paragraph 36, wherein R 6 W is selected from hydrogen and methyl (eg W is selected from NH and NMe).
[0205] 38. A compound according to paragraph 36 or paragraph 37, wherein R 6 is hydrogen (e.g. W is NH).
[0206] 39. A compound according to paragraph 36 or paragraph 37, wherein R 6 is methyl (eg, W is NMe).
[0207] 40. A compound according to any one of paragraphs 1 to 39, wherein when R 3 When it is a group represented by formula (2) or formula (2a), Y is selected from hydrogen, C2 alkenyl and halo-C2 alkenyl. The halo-C2 alkenyl is a C2 alkenyl substituted by one or more halogens.
[0208] 41. A compound according to paragraph 40, wherein the halo-C2 alkenyl is a C2 alkenyl substituted by one, two or three halogens.
[0209] 42. A compound according to paragraph 41, wherein the halo-C2 alkenyl is a C2 alkenyl substituted by one halogen.
[0210] 43. A compound according to any one of paragraphs 40 to 42, wherein the halogen of the halo-C2 alkenyl group is each independently selected from chlorine (-Cl), bromine (-Br) and fluorine (-F).
[0211] 44. A compound according to paragraph 43, wherein the halogen of the halo-C2 alkenyl group is fluorine (—F).
[0212] 45. A compound according to paragraph 40, wherein Y is hydrogen.
[0213] 46. A compound according to paragraph 40, wherein Y is C2 alkenyl.
[0214] 47. A compound according to paragraph 40, wherein Y is halo-C2 alkenyl (eg, Y is C2 alkenyl substituted with one or more halo groups).
[0215] 48. A compound according to any one of paragraphs 1 to 31, wherein R 3 Yes-[C(R 7 )2] n -X.
[0216] 49. A compound according to any one of paragraphs 1 to 31 or 48, wherein when R 3 Yes-[C(R 7 )2] n -X, then each R 7 are independently selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 The halo-C 1-6 Alkyl is a C substituted with one or more halogens. 1-6 Alkyl. The halogenated-C 2-6 Alkenyl is a C 2-6 Alkenyl.
[0217] 50. A compound according to paragraph 49, wherein the halogenated-C 1-6 Alkyl is a C substituted with one, two or three halogens. 1-6 alkyl.
[0218] 51. A compound according to paragraph 50, wherein the halogenated-C 1-6 Alkyl is a C substituted with a halogen 1-6 alkyl.
[0219] 52. A compound according to paragraph 49, wherein the halo-C 2-6 Alkenyl is a C substituted with one, two or three halogens. 2-6 Alkenyl.
[0220] 53. A compound according to paragraph 52, wherein the halogenated-C 2-6 Alkenyl is a C substituted with a halogen 2-6 Alkenyl.
[0221] 54. A compound according to any one of paragraphs 49 to 53, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of the alkenyl group is each independently selected from chlorine (—Cl), bromine (—Br) and fluorine (—F).
[0222] 55. A compound according to paragraph 54, wherein the halogenated-C 1-6 Alkyl and the halo-C 2-6 The halogen of alkenyl is fluorine (-F).
[0223] 56. A compound according to any one of paragraphs 1 to 55, wherein when R 3 Yes-[C(R 7 )2] n -X, then each R 7 are independently selected from hydrogen, C 1-6 Alkyl and C 2-6 The C 1-6 The alkyl group is unsubstituted. 2-6 An alkenyl group is unsubstituted.
[0224] 57. A compound according to any one of paragraphs 1 to 55, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and the other R on each carbon atom 7 Selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 Alkenyl (eg R 3 Yes - [CHR 7 ] n -X).
[0225] 58. A compound according to paragraph 57, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and the other R on each carbon atom 7 Selected from hydrogen, C 1-6 Alkyl and C 2-6 Alkenyl.
[0226] 59. A compound according to paragraph 58, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and at least one R 7 Selected from C 1-6 Alkyl and C 2-6 Alkenyl.
[0227] 60. A compound according to paragraph 59, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and the other R 7One of them is C 2-6 Alkenyl.
[0228] 61. A compound according to any one of paragraphs 1 to 55, wherein when R 3 Yes-[C(R 7 )2] n -X, then all R 7 is hydrogen (e.g. R 3 Yes - [CH2] n -X).
[0229] 62. A compound according to any one of paragraphs 1 to 61, wherein when R 3 Yes-[C(R 7 )2] n When -X, X is selected from halogen and -OH. Preferably, X is selected from fluorine (-F) and -OH.
[0230] 63. A compound according to any one of paragraphs 1 to 61, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is a halogen, then X is chlorine (-Cl), bromine (-Br) and fluorine (-F).
[0231] 64. The compound according to paragraph 63, wherein X is fluoro (-F).
[0232] 65. A compound according to any one of paragraphs 1 to 31 or 48 to 62, wherein X is -OH.
[0233] 66. A compound according to any one of paragraphs 1 to 31 or 48 to 61, wherein X is -SH.
[0234] 67. A compound according to any one of paragraphs 1 to 31 or 48 to 61, wherein when R 3 Yes-[C(R 7 )2] n -X and X is -OZ, -SZ or -SSZ, then Z is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
[0235] 68. A compound according to any one of paragraphs 1 to 31, 48 to 61 or 67, wherein when R 3 Yes-[C(R 7 )2] n -X and X is -OZ, -SZ or -SSZ, then Z is selected from C 6-10 aryl and 5- to 10-membered heteroaryl.
[0236] 69. A compound according to any one of paragraphs 1 to 31, 48 to 61, 67 or 68, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is -OZ, -SZ or -SSZ, then Z is selected from phenyl and 5-membered, 6-membered, 9-membered or 10-membered heteroaryl.
[0237] 70. A compound according to any one of paragraphs 1 to 31, 48 to 61 or 67 to 69, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is -OZ, -SZ or -SSZ, then Z is selected from phenyl and 6-membered or 9-membered heteroaryl.
[0238] 71. A compound according to any one of paragraphs 1 to 31, 48 to 61 or 67 to 70, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is -OZ, -SZ or -SSZ, then Z is selected from phenyl, pyridyl and benzothiazolyl.
[0239] 72. A compound according to any one of paragraphs 1 to 31, 48 to 61 or 67 to 71, wherein when Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, then the C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, chlorine, bromine, fluorine, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0240] 73. A compound according to paragraph 72, wherein said C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0241] 74. A compound according to paragraph 73, wherein said C 6-10 The aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally substituted with one or more groups selected from -OH and -NH2.
[0242] 75. A compound according to any one of paragraphs 1 to 31, 48 to 61 or 67 to 74, wherein X is -OZ, -SZ or -SSZ.
[0243] 76. The compound according to paragraph 75, wherein X is -OZ.
[0244] 77. The compound according to paragraph 75, wherein X is -SZ.
[0245] 78. The compound according to paragraph 75, wherein X is -SSZ.
[0246] 79. A compound according to any one of paragraphs 1 to 31 or 48 to 61, wherein when R 3 Yes-[C(R 7 )2] n When -X, X is selected from 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0247] 80. The compound according to paragraph 79, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
[0248] 81. The compound according to paragraph 80, wherein X is a 5- to 10-membered heteroaryl.
[0249] 82. The compound according to paragraph 81, wherein X is a 5-membered, 6-membered, 9-membered or 10-membered heteroaryl.
[0250] 83. The compound according to paragraph 82, wherein X is a 5-membered or 6-membered heteroaryl.
[0251] 84. The compound according to paragraph 83, wherein X is triazolyl.
[0252] 85. A compound according to any one of paragraphs 1 to 31, 48 to 61 or 79 to 84, wherein when X is selected from 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, then the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, chlorine, bromine, fluorine, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0253] 86. A compound according to paragraph 85, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl are optionally selected from -OH, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0254] 87. A compound according to paragraph 86, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally substituted with one or more groups selected from -OH and -NH2.
[0255] 88. A compound according to any one of paragraphs 1 to 31, wherein R 3 Yes -CH=CR 6 R 7 .
[0256] 89. A compound according to paragraph 88, wherein R 6 is H (for example R 3 Yes -CH=CHR 7 ).
[0257] 90. A compound according to paragraph 88 or paragraph 89, wherein R 7 Selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 The halo-C 1-6 Alkyl is a C substituted with one or more halogens. 1-6 Alkyl. The halogenated-C 2-6 Alkenyl is a C 2-6 Alkenyl.
[0258] 91. A compound according to paragraph 90, wherein the halogenated-C 1-6 Alkyl is a C substituted with one, two or three halogens. 1-6 alkyl.
[0259] 92. A compound according to paragraph 91, wherein the halogenated-C 1-6 Alkyl is a C substituted with a halogen 1-6 alkyl.
[0260] 93. A compound according to any one of paragraphs 90 to 92, wherein the halogenated-C 2-6 Alkenyl is a C substituted with one, two or three halogens. 2-6 Alkenyl.
[0261] 94. A compound according to paragraph 93, wherein the halo-C 2-6Alkenyl is a C substituted with a halogen 2-6 Alkenyl.
[0262] 95. A compound according to any one of paragraphs 90 to 94, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of the alkenyl group is each independently selected from chlorine (—Cl), bromine (—Br) and fluorine (—F).
[0263] 96. A compound according to paragraph 95, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of alkenyl is fluorine (-F).
[0264] 97. A compound according to any one of paragraphs 90 to 96, wherein R 7 Selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 Alkenyl.
[0265] 98. A compound according to paragraph 97, wherein R 7 It is halogenated-C 2-6 Alkenyl.
[0266] 99. A compound according to any one of paragraphs 1 to 31, wherein R 3 Yes-CR 7 =NN(R 6 )2.
[0267] 100. The compound according to paragraph 99, wherein R 7 Selected from H and C 1-6 alkyl.
[0268] 101. A compound according to paragraph 100, wherein said R 7 It's H.
[0269] 102. A compound according to any one of paragraphs 99 to 101, wherein two R 6 are all hydrogen (e.g. R 3 Yes-CR 7 =N-NH2).
[0270] 103. A compound according to any one of paragraphs 1 to 31, wherein R 3 is selected from 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and the 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
[0271] 104. A compound according to paragraph 103, wherein R 3is selected from 5-membered, 6-membered, 9-membered or 10-membered heteroaryl or 5-membered, 6-membered, 9-membered or 10-membered heterocycloalkyl.
[0272] 105. A compound according to paragraph 104, wherein R 3 is selected from 5-membered or 6-membered heteroaryl and 5-membered or 6-membered heterocycloalkyl.
[0273] 107. The compound according to paragraph 105, wherein R 3 It is a 5-membered or 6-membered heterocycloalkyl group.
[0274] 108. A compound according to paragraph 107, wherein R 3 It is an imidazoline group.
[0275] 109. A compound according to any one of paragraphs 1 to 31 or 103 to 108, wherein when R 3 When selected from 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0276] 110. The compound according to paragraph 109, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally substituted with one or more groups selected from -OH and -NH2.
[0277] 111. A compound according to any one of paragraphs 1 to 110, wherein each n is an integer independently selected from 1, 2, 3, 4 and 5 (e.g., when R 3 It is represented by formula (2) or formula (2a) or -[C(R 7 )2] n -X).
[0278] 112. The compound according to paragraph 111, wherein each n is an integer independently selected from 1, 2 and 3.
[0279] 113. A compound according to paragraph 112, wherein n is 1 (eg when X is -OH).
[0280] 114. A compound according to paragraph 112, wherein n is 3 (eg when X is -OH).
[0281] 115. A compound according to paragraph 112, wherein n is 2 (e.g. when R 3 is the formula (2)).
[0282] 116. A compound according to any one of paragraphs 1 to 115, wherein the compound of formula (10) is not one of the following:
[0283]
[0284]
[0285] 117. The compound according to any one of paragraphs 1 to 116 is selected from:
[0286]
[0287]
[0288]
[0289]
[0290] 118. A compound according to any one of paragraphs 1 to 117, selected from:
[0291]
[0292]
[0293] The present invention also provides a compound of formula (10) as defined in paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, for use in treating or preventing a DHCR24-mediated disorder. This aspect of the present invention also provides a method for treating or preventing a DHCR24-mediated disorder. The method comprises administering a compound of formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, to a subject.
[0294] The second aspect of the present invention as described herein relates to a compound of formula (1), or a salt, solvate, hydrate or prodrug thereof. The salt is preferably a pharmaceutically acceptable salt.
[0295] 2.1. In the second aspect of the present invention, the compound of formula (1) is:
[0296]
[0297] in:
[0298] G is a fused ring system selected from the following:
[0299]
[0300] B is selected from:
[0301]
[0302] R1 Selected from hydrogen, -C(=O)R 6 and C 1-6 alkyl;
[0303] R 2 Selected from hydrogen and C 1-6 alkyl;
[0304] R 3 A group selected from the group represented by formula (2), -[C(R 7 )2] n -X, -C(=O)NHOR 8 、-C(=O)OR 8 , -CR 7 =NN(R 6 )2, -CH=CR 6 R 7 , C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0305]
[0306] n is an integer from 1 to 6;
[0307] W is selected from O, S and NR 6 ;
[0308] Y is selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, amino-C 1-6 Alkyl, (mono-C 1-6 Alkylamino)C 1-6 Alkyl and (di-C 1-6 Alkylamino)C 1-6 Alkyl, where C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens;
[0309] X is selected from halogen, -OH, -SH, -N(R 6 )2, -OZ, -SZ, -SSZ, -C(=O)R 7 , C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups;
[0310] Each R 4 are independently selected from hydrogen and C 1-6 alkyl;
[0311] R 5 Selected from hydrogen and C 1-6 alkyl;
[0312] Each R 6 are independently selected from hydrogen and C 1-6 alkyl;
[0313] Each R 7 Independently selected from H, C 1-6 Alkyl and C 2-6 Alkenyl, where C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens;
[0314] R 8 Selected from C 1-6 Alkyl and C 2-6 alkenyl, and
[0315] Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0316] 2.2. The compound according to paragraph 2.1, which is represented by formula (1a):
[0317]
[0318] 2.3. The compound according to paragraph 2.1, which is represented by formula (1b):
[0319]
[0320] 2.4. The compound according to paragraph 2.1, which is represented by formula (1p):
[0321]
[0322] 2.5. The compound according to paragraph 2.1, which is represented by formula (1q):
[0323]
[0324] 2.6. A compound according to any one of paragraphs 2.1, 2.2 or 2.4, which is represented by formula (1ap):
[0325]
[0326] 2.7. A compound according to any one of paragraphs 2.1, 2.2 or 2.5, which is represented by formula (1aq):
[0327]
[0328] 2.8. A compound according to any one of paragraphs 2.1, 2.3 or 2.4, which is represented by formula (1bp):
[0329]
[0330] 2.9. A compound according to any one of paragraphs 2.1, 2.3 or 2.5, which is represented by formula (1bq):
[0331]
[0332] 2.10. A compound according to any one of paragraphs 2.1 to 2.9, wherein R 1 is hydrogen or -C(=O)R 6 .
[0333] 2.11. A compound according to any one of paragraphs 2.1 to 2.10, wherein R 1 It's hydrogen.
[0334] 2.12. Compounds according to any one of paragraphs 2.1 to 2.10, wherein R 1 Yes-C(=O)R 6 .
[0335] 2.13. Compounds according to any one of paragraphs 2.1 to 2.12, wherein when R 1 Yes-C(=O)R 6 When R 6 It is C 1-6 Alkyl (such as R 6 Yes -C(=O)-C 1-6 alkyl).
[0336] 2.14. Compounds according to paragraph 2.13, wherein R 6 is methyl or ethyl (e.g. R1 is -C(=O)Me or -C(=O)Et).
[0337] 2.15. Compounds according to paragraph 2.14, wherein R 6 is a methyl group (e.g. R 1 is -C(=O)-Me).
[0338] 2.16. A compound according to any of paragraphs 2.1 to 2.15, wherein G is:
[0339]
[0340] 2.17. Compounds according to paragraph 2.16, wherein G is:
[0341]
[0342] 2.18. A compound according to any one of paragraphs 2.1 to 2.17, wherein R 5 is selected from hydrogen, methyl and ethyl.
[0343] 2.19. Compounds according to paragraph 2.18, wherein R 5 is selected from hydrogen and methyl.
[0344] 2.20. A compound according to any one of paragraphs 2.1 to 2.19, wherein R 5 It's hydrogen.
[0345] 2.21. A compound according to any one of paragraphs 2.1 to 2.19, wherein R 5 It's methyl.
[0346] 2.22. A compound according to any one of paragraphs 2.1 to 2.21, wherein each R 4 are independently selected from hydrogen, methyl and ethyl.
[0347] 2.23. A compound according to any one of paragraphs 2.1 to 2.22, wherein each R 4 are independently selected from hydrogen and methyl.
[0348] 2.24. A compound according to any one of paragraphs 2.1 to 2.23, wherein at least one R 4 It's hydrogen.
[0349] 2.25. A compound according to any one of paragraphs 2.1 to 2.24, wherein at least one R 4 It's methyl.
[0350] 2.26. A compound according to any one of paragraphs 2.1 to 2.24, wherein both R4 It's all hydrogen.
[0351] 2.27. A compound according to any one of paragraphs 2.1 to 2.23, wherein both R 4 They are all methyl.
[0352] 2.28. A compound according to any one of paragraphs 2.1 to 2.27, wherein B is selected from:
[0353]
[0354] 2.29. A compound according to any of paragraphs 2.1 to 2.28, wherein B is:
[0355]
[0356] 2.30. A compound according to any of paragraphs 2.1 to 2.28, wherein B is:
[0357]
[0358] 2.31. A compound according to any of paragraphs 2.1 to 2.28, wherein B is:
[0359]
[0360] 2.32. A compound according to any one of paragraphs 2.1 to 2.31, wherein R 2 It's hydrogen.
[0361] 2.33. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 is a group represented by formula (2):
[0362]
[0363] 2.34. A compound according to any one of paragraphs 2.1 to 2.33, wherein when R 3 When it is a group represented by formula (2), each R 6 are independently selected from hydrogen, methyl and ethyl.
[0364] 2.35. A compound according to any one of paragraphs 2.1 to 2.34, wherein when R 3 When it is a group represented by formula (2), at least one R 6 It's hydrogen.
[0365] 2.36. A compound according to any one of paragraphs 2.1 to 2.35, wherein R 3 is a group represented by formula (2a):
[0366]
[0367] 2.37. A compound according to any one of paragraphs 2.1 to 2.36, wherein when R 3 is a group represented by formula (2) or formula (2a) and when W is NR 6 When R 6 W is selected from hydrogen, methyl and ethyl (eg W is selected from NH, NMe and NEt).
[0368] 2.38. Compounds according to paragraph 2.37, wherein R 6 W is selected from hydrogen and methyl (eg W is selected from NH and NMe).
[0369] 2.39. Compounds according to paragraph 2.37 or paragraph 2.38, wherein R 6 is hydrogen (e.g. W is NH).
[0370] 2.40. A compound according to paragraph 2.37 or paragraph 2.38, wherein R 6 is methyl (eg, W is NMe).
[0371] 2.41. A compound according to any one of paragraphs 2.1 to 2.40, wherein when R 3 When it is a group represented by formula (2) or formula (2a), Y is selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl, halo-C 2-6 Alkenyl, amino-C 1-6 Alkyl, (mono-C 1-6 Alkylamino)C 1-6 Alkyl and (di-C 1-6 Alkylamino)C 1-6 Alkyl. The halogenated-C 1-6 Alkyl is a C substituted with one or more halogens. 1-6 Alkyl. The halogenated-C 2-6 Alkenyl is a C 2-6 Alkenyl.
[0372] 2.42. Compounds according to paragraph 2.41, wherein the halo-C 1-6 Alkyl is a C substituted with one, two or three halogens. 1-6 alkyl.
[0373] 2.43. Compounds according to paragraph 2.42, wherein the halo-C 1-6 Alkyl is a C substituted with a halogen 1-6 alkyl.
[0374] 2.44. A compound according to any one of paragraphs 2.41 to 2.43, wherein the halo-C 2-6 Alkenyl is a C substituted with one, two or three halogens. 2-6 Alkenyl.
[0375] 2.45. Compounds according to paragraph 2.44, wherein the halo-C 2-6 Alkenyl is a C substituted with a halogen 2-6 Alkenyl.
[0376] 2.46. A compound according to any one of paragraphs 2.41 to 2.45, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of the alkenyl group is each independently selected from chlorine (—Cl), bromine (—Br) and fluorine (—F).
[0377] 2.47. Compounds according to paragraph 2.46, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of alkenyl is fluorine (-F).
[0378] 2.48. A compound according to any one of paragraphs 2.41 to 2.47, wherein R 3 is a group represented by formula (2) or formula (2a), Y is selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, halo-C 2-6 Alkenyl, amino-C 1-6 Alkyl, (mono-C 1-6 Alkylamino)C 1-6 Alkyl and (di-C 1-6 Alkylamino)C 1-6 alkyl.
[0379] 2.49. Compounds according to any of paragraphs 2.41 to 2.48 wherein Y is hydrogen.
[0380] 2.50. A compound according to any one of paragraphs 2.41 to 2.48, wherein Y is C 1-6 alkyl.
[0381] 2.51. Compounds according to paragraph 2.50, wherein Y is C 1-3 alkyl.
[0382] 2.52. A compound according to any one of paragraphs 2.41 to 2.48, wherein Y is C 2-6 Alkenyl.
[0383] 2.53. Compounds according to paragraph 2.52, wherein Y is C 2-4 Alkenyl.
[0384] 2.54. A compound according to any one of paragraphs 2.41 to 2.48, wherein Y is a halo-C 2-6 Alkenyl (eg, Y is C substituted with one or more halogen groups) 2-6 alkenyl).
[0385] 2.55. Compounds according to paragraph 2.54, wherein Y is a halo-C 2-4 Alkenyl.
[0386] 2.56. A compound according to any one of paragraphs 2.41 to 2.48, wherein Y is selected from amino-C 1-6 Alkyl, (mono-C 1-6 Alkylamino)C 1-6 Alkyl and (di-C 1-6 Alkylamino)C 1-6 alkyl.
[0387] 2.57. Compounds according to paragraph 2.56, wherein Y is selected from amino-C 1-3 Alkyl, (mono-C 1-3 Alkylamino)C 1-3 Alkyl and (di-C 1-3 Alkylamino)C 1-3 alkyl.
[0388] 2.58. A compound according to any one of paragraphs 2.1 to 2.36 or 2.41 to 2.57, wherein when R 3 When it is a group represented by formula (2) or formula (2a), W is S.
[0389] 2.59. Compounds according to paragraph 2.58, wherein Y is hydrogen or C 1-6 alkyl.
[0390] 2.60. A compound according to any one of paragraphs 2.1 to 2.57, wherein when R 3 When it is a group represented by formula (3) or formula (3a), W is O or NR 6 .
[0391] 2.61. Compounds according to paragraph 2.60, wherein when R 3 When it is a group represented by formula (3) or formula (3a), W is O.
[0392] 2.62. Compounds according to paragraph 2.60, wherein when R 3 When it is a group represented by formula (3) or formula (3a), W is NR 6.
[0393] 2.63. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 Yes-[C(R 7 )2] n -X.
[0394] 2.64. A compound according to any one of paragraphs 2.1 to 2.31 or 2.63, wherein when R 3 Yes-[C(R 7 )2] n -X, then each R 7 are independently selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 The halo-C 1-6 Alkyl is a C substituted with one or more halogens. 1-6 Alkyl. The halogenated-C 2-6 Alkenyl is a C 2-6 Alkenyl.
[0395] 2.65. Compounds according to paragraph 2.64, wherein the halo-C 1-6 Alkyl is a C substituted with one, two or three halogens. 1-6 alkyl.
[0396] 2.66. Compounds according to paragraph 2.65, wherein the halo-C 1-6 Alkyl is a C substituted with a halogen 1-6 alkyl.
[0397] 2.67. A compound according to any one of paragraphs 2.64 to 2.66, wherein the halo-C 2-6 Alkenyl is a C substituted with one, two or three halogens. 2-6 Alkenyl.
[0398] 2.68. Compounds according to paragraph 2.67, wherein the halo-C 2-6 Alkenyl is a C substituted with a halogen 2-6 Alkenyl.
[0399] 2.69. A compound according to any one of paragraphs 2.64 to 2.68, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of the alkenyl group is each independently selected from chlorine (—Cl), bromine (—Br) and fluorine (—F).
[0400] 2.70. Compounds according to paragraph 2.69, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of alkenyl is fluorine (-F).
[0401] 2.71. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 or 2.64, wherein when R 3 Yes-[C(R 7 )2] n -X, then each R 7 are independently selected from hydrogen, C 1-6 Alkyl and C 2-6 The C 1-6 The alkyl group is unsubstituted. 2-6 An alkenyl group is unsubstituted.
[0402] 2.72. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.71, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and the other R on each carbon atom 7 Selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 Alkenyl (eg R 3 Yes - [CHR 7 ] n -X).
[0403] 2.73. Compounds according to paragraph 2.72, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and the other R on each carbon atom 7 Selected from hydrogen, C 1-6 Alkyl and C 2-6 Alkenyl.
[0404] 2.74. Compounds according to paragraph 2.73, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and at least one R 7 Selected from C 1-6 Alkyl and C 2-6 Alkenyl.
[0405] 2.75. Compounds according to paragraph 2.74, wherein when R 3 Yes-[C(R 7 )2] n -X, then at least one R on each carbon atom 7 is hydrogen and the other R 7 One of them is C 2-6 Alkenyl.
[0406] 2.76. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.73, wherein when R 3 Yes-[C(R 7 )2] n -X, then all R 7 is hydrogen (e.g. R 3 Yes - [CH2] n -X).
[0407] 2.77. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.76, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is a halogen, then X is chlorine (-Cl), bromine (-Br) and fluorine (-F).
[0408] 2.78. Compounds according to paragraph 2.77 wherein X is fluoro (-F).
[0409] 2.79. Compounds according to any of paragraphs 2.1 to 2.32 or 2.63 to 2.76, wherein X is -OH.
[0410] 2.80. A compound according to any of paragraphs 2.1 to 2.32 or 2.63 to 2.76 wherein X is -SH.
[0411] 2.81. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.76, wherein when R 3 Yes-[C(R 7 )2] n -X and X is -N(R 6 )2, then each R 6 are independently selected from hydrogen and C 1-3 alkyl.
[0412] 2.82. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.81, wherein when R 3 Yes-[C(R 7 )2] n -X and X is -N(R6 )2, then at least one R 6 is hydrogen and the other R 6 Selected from hydrogen and C 1-6 Alkyl (eg X is -NHR 6 ).
[0413] 2.83. A compound according to any one of paragraphs 2.81 or 2.82, wherein both R 6 are all hydrogen (eg X is -NH2).
[0414] 2.84. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.81 to 2.83, wherein X is -N(R 6 )2.
[0415] 2.85. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.76, wherein when R 3 Yes-[C(R 7 )2] n -X and X is -OZ, -SZ or -SSZ, then Z is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
[0416] 2.86. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.85, wherein when R 3 Yes-[C(R 7 )2] n -X and X is -OZ, -SZ or -SSZ, then Z is selected from C 6-10 aryl and 5- to 10-membered heteroaryl.
[0417] 2.87. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76, 2.85 or 2.86, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is -OZ, -SZ or -SSZ, then Z is selected from phenyl and 5-membered, 6-membered, 9-membered or 10-membered heteroaryl.
[0418] 2.88. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.85 to 2.87, wherein when R 3 Yes-[C(R 7 )2] nWhen -X and X is -OZ, -SZ or -SSZ, then Z is selected from phenyl and 6-membered or 9-membered heteroaryl.
[0419] 2.89. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.85 to 2.88, wherein when R 3 Yes-[C(R 7 )2] n When -X and X is -OZ, -SZ or -SSZ, then Z is selected from phenyl, pyridyl and benzothiazolyl.
[0420] 2.90. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.85 to 2.89, wherein when Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, then the C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, chlorine, bromine, fluorine, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0421] 2.91. A compound according to paragraph 2.90, wherein said C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0422] 2.92. Compounds according to paragraph 2.91, wherein said C 6-10 The aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally substituted with one or more groups selected from -OH and -NH2.
[0423] 2.93. A compound according to any of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.85 to 2.92 wherein X is -OZ, -SZ or -SSZ.
[0424] 2.94. A compound according to paragraph 2.93 wherein X is -OZ.
[0425] 2.95. A compound according to paragraph 2.93 wherein X is -SZ.
[0426] 2.96. A compound according to paragraph 2.93 wherein X is -SSZ.
[0427] 2.97. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.76, wherein X is -C(=O)R 7 .
[0428] 2.98. A compound according to any one of paragraphs 2.1 to 2.32 or 2.63 to 2.76, wherein when R 3 Yes-[C(R 7 )2] n -X, X is selected from C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0429] 2.99. Compounds according to paragraph 2.98, wherein X is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
[0430] 2.100. Compounds according to paragraph 2.99, wherein X is selected from C 6-10 aryl and 5- to 10-membered heteroaryl.
[0431] 2.101. A compound according to paragraph 2.100 wherein X is selected from phenyl and 5-membered, 6-membered, 9-membered or 10-membered heteroaryl.
[0432] 2.102. A compound according to paragraph 2.101 wherein X is a 5- or 6-membered heteroaryl.
[0433] 2.103. A compound according to paragraph 2.102 wherein X is triazolyl.
[0434] 2.104. A compound according to any one of paragraphs 2.1 to 2.32, 2.63 to 2.76 or 2.98 to 2.103, wherein when X is selected from C 6-10 aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, then the C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, chlorine, bromine, fluorine, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0435] 2.105. A compound according to paragraph 2.104, wherein said C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0436] 2.106. A compound according to paragraph 2.105, wherein said C 6-10 The aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally substituted with one or more groups selected from -OH and -NH2.
[0437] 2.107. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 Yes -C(=O)NHOR 8 .
[0438] 2.108. A compound according to paragraph 2.107, wherein R 8 It is C 1-6 alkyl.
[0439] 2.109. A compound according to paragraph 2.108, wherein R 8 It is C 1-3 alkyl.
[0440] 2.110. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 Yes -C(=O)OR 8 .
[0441] 2.111. A compound according to paragraph 2.110, wherein R 8 It is C 2-6 Alkenyl.
[0442] 2.112. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 Yes-CR 7 =NN(R 6 )2.
[0443] 2.113. A compound according to paragraph 2.112, wherein R 7 Selected from H and C 1-6 alkyl.
[0444] 2.114. A compound according to paragraph 2.113, wherein R 7 It's H.
[0445] 2.115. A compound according to any one of paragraphs 2.112 to 2.114, wherein both R 6 are all hydrogen (e.g. R 3 Yes-CR 7 =N-NH2).
[0446] 2.116. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 Yes -CH=CR 6 R 7 .
[0447] 2.117. A compound according to paragraph 2.116, wherein R 6 is H (for example R 3 Yes -CH=CHR 7 ).
[0448] 2.118. A compound according to paragraph 2.116 or paragraph 2.117, wherein R 7 Selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 The halo-C 1-6 Alkyl is a C substituted with one or more halogens. 1-6 Alkyl. The halogenated-C 2-6 Alkenyl is a C 2-6 Alkenyl.
[0449] 2.119. Compounds according to paragraph 2.118, wherein the halo-C 1-6 Alkyl is a C substituted with one, two or three halogens. 1-6 alkyl.
[0450] 2.120. A compound according to paragraph 2.119, wherein the halo-C 1-6 Alkyl is a C substituted with a halogen 1-6 alkyl.
[0451] 2.121. A compound according to any one of paragraphs 2.118 to 2.120, wherein the halo-C 2-6 Alkenyl is a C substituted with one, two or three halogens. 2-6 Alkenyl.
[0452] 2.122. Compounds according to paragraph 2.121, wherein the halo-C 2-6 Alkenyl is a C substituted with a halogen 2-6 Alkenyl.
[0453] 2.123. A compound according to any one of paragraphs 2.118 to 2.122, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of the alkenyl group is each independently selected from chlorine (—Cl), bromine (—Br) and fluorine (—F).
[0454] 2.124. Compounds according to paragraph 2.123, wherein the halo-C 1-6 Alkyl and the halo-C 2-6 The halogen of alkenyl is fluorine (-F).
[0455] 2.125. A compound according to any one of paragraphs 2.118 to 2.124, wherein R 7 Selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 Alkenyl.
[0456] 2.126. Compounds according to paragraph 2.125, wherein R 7 It is halogenated-C 2-6 Alkenyl.
[0457] 2.127. A compound according to any one of paragraphs 2.1 to 2.32, wherein R 3 Selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
[0458] 2.128. A compound according to any one of paragraphs 2.1 to 2.32 or 2.127, wherein R 3 is selected from 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl.
[0459] 2.129. Compounds according to paragraph 2.128, wherein R 3 is selected from 5-membered, 6-membered, 9-membered or 10-membered heteroaryl and 5-membered, 6-membered, 9-membered or 10-membered heterocycloalkyl.
[0460] 2.130. A compound according to paragraph 2.129, wherein R 3 is selected from 5-membered or 6-membered heteroaryl and 5-membered or 6-membered heterocycloalkyl.
[0461] 2.131. A compound according to paragraph 2.130, wherein R 3 It is a 5-membered or 6-membered heterocycloalkyl group.
[0462] 2.132. Compounds according to paragraph 2.131, wherein R 3It is an imidazoline group.
[0463] 2.133. A compound according to any one of paragraphs 2.127 to 2.132, wherein C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, -NH2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted with one or more groups.
[0464] 2.134. A compound according to paragraph 2.133, wherein said C 6-10 The aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally substituted with one or more groups selected from -OH and -NH2.
[0465] 2.135. A compound according to any of paragraphs 2.1 to 2.134 wherein n is an integer selected from 1, 2, 3, 4 and 5.
[0466] 2.136. A compound according to paragraph 2.135 wherein n is an integer selected from 1, 2 and 3.
[0467] 2.137. Compounds according to paragraph 2.136, wherein n is 1 (eg when X is -OH or -OZ).
[0468] 2.138. Compounds according to paragraph 2.136 wherein n is 3 (eg when X is -OH or -OZ).
[0469] 2.139. Compounds according to paragraph 2.136, wherein n is 2 (eg when R 3 is the formula (2)).
[0470] 2.140. The compound according to paragraph 2.1 is selected from:
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478] In the second aspect of the present invention, the compound of formula (1) is preferably:
[0479]
[0480] Another aspect of the present invention is to provide a pharmaceutical composition comprising a compound of formula (1) as defined in, for example, paragraphs 2.1 to 2.140 above, or a compound of formula (10) as defined in, for example, paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable excipient.
[0481] In another aspect, the invention provides a compound of formula (1) as defined in, for example, paragraphs 2.1 to 2.140 above, or a compound of formula (10) as defined in, for example, paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for use in therapy and / or as a medicament.
[0482] In another aspect, the invention provides the use of a compound of formula (1) as defined in, for example, paragraphs 2.1 to 2.140 above, or a compound of formula (10) as defined in, for example, paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in the preparation of a medicament for treating or preventing a DHCR24-mediated disorder.
[0483] Another aspect of the invention provides a method for inhibiting DHCR24 activity in vivo or in vitro. The in vivo or in vitro method comprises contacting a cell with a compound of formula (1) as defined in, for example, paragraphs 2.1 to 2.140 above, or a compound of formula (10) as defined in, for example, paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein. Alternatively, the in vivo method may comprise administering to a subject a compound of formula (1) as defined in, for example, paragraphs 2.1 to 2.140 above, or a compound of formula (10) as defined in, for example, paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein.
[0484] In another aspect, the invention provides a combination comprising a compound of formula (1) as defined in, for example, paragraphs 2.1 to 2.140 above, or a compound of formula (10) as defined in, for example, paragraphs 1 to 118 above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and one or more additional therapeutic agents.
[0485] As a general feature of the invention, the DHCR24-mediated disorder may be selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD), multiple sclerosis, hepatocellular carcinoma, breast cancer, endometrial cancer, B-cell lymphoma, drug-resistant cancer and hepatitis C. Preferably, the DHCR24-mediated disorder is selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD), multiple sclerosis (MS) and a combination of non-alcoholic steatohepatitis (NASH) and atherosclerotic cardiovascular disease (asCVD).
[0486] Preferably, the DHCR24-mediated disorder is non-alcoholic steatohepatitis (NASH).
[0487] The DHCR24-mediated disorder is preferably atherosclerotic cardiovascular disease (asCVD).
[0488] The DHCR24-mediated disease is preferably multiple sclerosis (MS).
[0489] In general, a prodrug of a compound of formula (1) such as defined in paragraphs 2.1 to 2.140 above or a prodrug of a compound of formula (10) such as defined in paragraphs 1 to 118 above is an ester, amide, hydrazone or disulfide of a compound of formula (1) or (10), respectively. Preferably, the prodrug is an ester, amide or disulfide of a compound of formula (1) or (10). More preferably, the prodrug is an ester or amide of a compound of formula (1) or (10).
[0490] When the prodrug is an ester or an amide, the ester or amide group may be present in R in the above formula (1) or formula (10). 1 and / or R 3 At, preferably at R 1 When the prodrug is a disulfide, the disulfide group may be present in R in the above formula (1) or formula (10). 3 Place.
[0491] Although the present invention may relate to any compound or specific group of compounds defined herein by way of optional, preferred or suitable features or in terms of some specific embodiments, the present invention may also relate to any compound or specific group of compounds specifically excluding such optional, preferred or suitable features or some specific embodiments.
[0492] Suitably, the present invention excludes any individual compound that does not possess the biological activity defined herein.
[0493] Salts and solvates
[0494] Compounds described herein (including final products and intermediates) can be separated and used by themselves, or can be separated in the form of salts (suitably pharmaceutically acceptable salts). It should be understood that, unless otherwise stated, the terms "salt" and "salt form" are used in combination with themselves or with another or more terms to cover all inorganic and organic salts, including industrially acceptable salts as defined herein and pharmaceutically acceptable salts as defined herein. As used herein, industrially acceptable salts are salts that are generally suitable for manufacture and / or processing (including purification) and for transportation and storage, but may not be salts that are generally used for clinical or therapeutic purposes. Industrially acceptable salts can be prepared on a laboratory scale, i.e., several grams or less, or on a larger scale, i.e., up to and including kilograms or more.
[0495] As used herein, pharmaceutically acceptable salts are salts that are generally chemically and / or physically compatible with the other ingredients constituting the formulation, and / or are generally physiologically compatible with its recipient. Industrially acceptable salts can be prepared on a laboratory scale, i.e., several grams or less, or prepared on a larger scale, i.e., up to and including kilograms or more. It should be understood that pharmaceutically acceptable salts are not limited to being generally used or approved by the FDA or equivalent foreign regulatory agencies for clinical or therapeutic use in people. It will be readily understood by those of ordinary skill in the art that some salts are both industrially acceptable salts and pharmaceutically acceptable salts. It should be understood that all such salts, including mixed salt forms, are within the scope of the present application.
[0496] In one embodiment, the compound of formula (1) or formula (10) is isolated as a pharmaceutically acceptable salt.
[0497] Suitable pharmaceutically acceptable salts of the compounds of the invention are, for example, acid-addition salts of the compounds of the invention with sufficient basicity, such as acid-addition salts in the case of, for example, inorganic or organic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid or maleic acid). In addition, suitable pharmaceutically acceptable salts of the compounds of the invention with sufficient acidity are alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), ammonium salts or salts in the case of organic bases providing physiologically acceptable cations, such as salts in the case of methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[0498] In general, the salt of the present application can be prepared in situ during the separation and / or purification of the compound (including intermediate), or by reacting the compound (or intermediate) with a suitable organic acid or inorganic acid or organic base or inorganic base (where appropriate) and separating the salt thus formed. The degree of ionization in the salt can vary from completely ionized to almost non-ionized. In fact, a variety of salts can be precipitated (with or without adding one or more co-solvents and / or anti-solvents) and collected by filtration, or the salt can be recovered by evaporating the solvent. The salt of the present application can also be formed by "salt conversion (salt switch)" or ion exchange / double displacement reaction (i.e., a reaction in which one ion (all or part) is replaced by another ion with the same charge). It will be appreciated by those skilled in the art that salts can be prepared and / or separated using a single method or a combination of methods.
[0499] Some representative salts include, but are not limited to, acetate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, sucrose salt, stearate, succinate, tartrate, toluenesulfonate, trifluoroacetate, and the like. Other examples of representative salts include alkali metal or alkaline earth metal cations, such as sodium, lithium, potassium, calcium, magnesium, and the like, and non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, lysine, arginine, benzathine, choline, tromethamine, diethanolamine, glycine, meglumine, ethanolamine, and the like.
[0500] Certain compounds of formula (1) or formula (10) may exist in solvated as well as unsolvated forms (eg, as hydrated forms). It is to be understood that the invention encompasses all such solvated forms which possess antiproliferative activity.
[0501] Polymorph
[0502] It is also understood that certain compounds of formula (1) or formula (10) may exhibit polymorphic forms and that the present invention encompasses all such forms that possess antiproliferative activity.
[0503] N-oxides
[0504] Compounds of formula (1) or (10) containing amine functional groups can also form N-oxides. References to compounds of formula (1) or (10) containing amine functional groups herein also include corresponding N-oxides. In the case where the compound contains several amine functional groups, one or more than one nitrogen atom can be oxidized to form N-oxides. Some specific examples of N-oxides are N-oxides of tertiary amines or nitrogen atoms of nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidant such as hydrogen peroxide or a peracid (such as peroxycarboxylic acid), see, for example, Advanced Organic Chemistry by Jerry March, 4th edition, Wiley Interscience, page. More specifically, N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), wherein the amine compound reacts with m-chloroperoxybenzoic acid (mCPBA), for example in an inert solvent such as dichloromethane.
[0505] Tautomer
[0506] Compounds of formula (1) or (10) may exist in a large number of different tautomeric forms and references to compounds of formula (1) or (10) include all such forms. For the avoidance of doubt, where a compound may exist in one of several tautomeric forms and only one is specifically described or shown, all other forms are included in formula (1) or (10). Some examples of tautomeric forms include ketone, enol and enolate forms, such as in the following tautomeric pairs: ketone / enol (illustrated below), pyrimidone / hydroxypyrimidine, imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol and nitro / acid-nitro.
[0507]
[0508] Isomers
[0509] Compounds that have the same molecular formula but differ in the nature or bonding sequence of their atoms or the arrangement of their atoms in space are called "isomers". Isomers whose atoms are arranged differently in space are called "stereoisomers". Stereoisomers that are not mirror images of each other are called "diastereomers", and those that are non-superimposable mirror images of each other are called "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, it may be a pair of enantiomers. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequential rules of Cahn and Prelog, or by the way in which the molecule rotates the plane of polarized light, and are called right-handed or left-handed (i.e., (+) or (-) isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal ratios of enantiomers is called a "racemic mixture".
[0510] Certain compounds of formula (1) or formula (10) may have one or more asymmetric centers and may therefore exist in a variety of stereoisomeric configurations. Therefore, such compounds may be synthesized and / or separated as mixtures of enantiomers and / or as individual (pure) enantiomers, and in the case of two or more asymmetric centers, may be synthesized and / or separated as single diastereomers and / or mixtures of diastereomers. It should be understood that the present application includes mixtures of all such enantiomers and diastereomers and all ratios thereof.
[0511] isotope
[0512] The compounds of the present invention are described herein using structural formulas which do not specifically list the mass numbers or isotopic ratios of the constituent atoms. Thus, the present application is intended to include compounds wherein the constituent atoms exist in isotopic forms in any ratio. For example, carbon atoms may be present in 12 C. 13 C and 14 C; hydrogen atoms can exist in any ratio 1 H. 2 H and 3 H exists in any ratio, etc. Preferably, the constituent atoms in the compounds of the present invention exist in the ratios of their naturally occurring isotopic forms.
[0513] Prodrugs and metabolites
[0514] The compound of formula (1) or formula (10) can be administered in the form of a prodrug, which decomposes in the human or animal body to release the compound of the present invention. Prodrugs can be used to change the physical properties and / or pharmacokinetic properties of the compound of the present invention. When the compound of the present invention contains a suitable group or substituent to which a property-modifying group can be attached, a prodrug can be formed. Some examples of prodrugs include ester derivatives that can be formed in vivo at the carboxyl or hydroxyl group in the compound of formula (1) or formula (10) and amide derivatives that can be formed in vivo at the carboxyl or amino group in the compound of formula (1) or formula (10).
[0515] Therefore, the present invention includes those compounds of formula (1) or (10) as defined above when obtainable by organic synthesis and when obtainable in the human or animal body by cleavage of their prodrugs. Therefore, the present invention includes those compounds of formula (1) or (10) produced by organic synthesis and also such compounds produced in the human or animal body by metabolizing precursor compounds, i.e., the compounds of formula (1) or (10) may be synthetically produced compounds or metabolically produced compounds.
[0516] A suitable pharmaceutically acceptable prodrug of a compound of formula (1) or (10) is a prodrug that is suitable, based on sound medical judgment, for administration to the human or animal body without undesirable pharmacological activity and without excessive toxicity.
[0517] Various forms of prodrugs have been described, for example in the following documents:
[0518] a) Methods in Enzymology , No. Volume 42 , pp. 309-396, edited by K. Widder et al. (Academic Press, 1985);
[0519] b) Design of Pro-drugs, edited by H.Bundgaard, (Elsevier, 1985);
[0520] c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, H.Bundgaard, pp. 113-191 (1991);
[0521] d) H.Bundgaard, Advanced Drug Delivery Reviews ,8 ,1-38(1992);
[0522] e) H.Bundgaard,et al., Journal of Pharmaceutical Sciences , 77 ,285(1988);
[0523] f)N.Kakeya,et al., Chem.Pharm.Bull. , 32 ,692(1984);
[0524] g) T.Higuchi and V.Stella, "Pro-Drugs as Novel Delivery Systems", ACSSymposium Series, Volume 14; and
[0525] h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.
[0526] Suitable pharmaceutically acceptable prodrugs of compounds of formula (1) or (10) having a carboxyl group are, for example, in vivo cleavable esters thereof. Esters may be present in R 1 and / or R 3 In vivo cleavable esters of compounds of formula (1) or (10) containing a carboxyl group are, for example, pharmaceutically acceptable esters that are cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically acceptable esters for the carboxyl group include C 1-6 Alkyl esters (such as methyl, ethyl and tert-butyl), C 1-6 Alkoxymethyl esters such as methoxymethyl ester, C 1-6 Alkanoyloxymethyl esters such as pivaloyloxymethyl ester, 3-phthaloyl ester, C 3-8 Cycloalkylcarbonyloxy-C 1-6 Alkyl esters such as cyclopentylcarbonyloxymethyl ester and 1-cyclohexylcarbonyloxyethyl ester, 2-oxo-1,3-dioxolyl methyl esters such as 5-methyl-2-oxo-1,3-dioxol-4-yl methyl ester and C 1-6 Alkoxycarbonyloxy-C 1-6 Alkyl esters include methoxycarbonyloxymethyl ester and 1-methoxycarbonyloxyethyl ester.
[0527] Suitable pharmaceutically acceptable prodrugs of compounds of formula (1) or (10) having a hydroxy group are, for example, esters or ethers thereof which can be cleaved in vivo. 1 and / or R 3In vivo cleavable esters or ethers of compounds of formula (1) or (10) containing hydroxyl groups are, for example, cleaved in the human or animal body to produce a pharmaceutically acceptable ester or ether of the parent hydroxyl compound. Suitable pharmaceutically acceptable ester-forming groups for hydroxyl groups include inorganic esters such as phosphates (including phosphoramidiccyclic esters). Other suitable pharmaceutically acceptable ester-forming groups for hydroxyl groups include C 1-10 Alkanoyl such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, C 1-10 Alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(C 1-6 )2-aminoformyl, 2-dialkylaminoacetyl and 2-carboxyacetyl. Some examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C 1-4 Suitable pharmaceutically acceptable ether-forming groups for the hydroxy group include α-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl.
[0528] Suitable pharmaceutically acceptable prodrugs of compounds of formula (1) or (10) having a carboxyl group are, for example, their in vivo cleavable amides, for example amides formed with amines such as ammonia, C 1-4 Alkylamines such as methylamine, (C 1-4 Alkyl)2 amines such as dimethylamine, N-ethyl-N-methylamine or diethylamine, C 1-4 Alkoxy-C 2-4 Alkylamines such as 2-methoxyethylamine, phenyl-C 1-4 Alkylamines such as benzylamine, and amino acids such as glycine or its esters. These groups may be present in R 1 and / or R 3 middle.
[0529] Suitable pharmaceutically acceptable prodrugs of the compounds of formula (1) or (10) having an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharmaceutically acceptable amides derived from the amino group include, for example, amides formed with: C 1-10 Alkanoyl groups include acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. Some examples of ring substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C 1-4 These groups may be present in R 1 and / or R 3 middle.
[0530] The in vivo effects of the compounds of formula (1) or (10) may be exerted in part by one or more metabolites formed in the human or animal body after the administration of the compounds of formula (1) or (10), respectively. As described above, the in vivo effects of the compounds of formula (1) or (10) may also be produced by metabolizing precursor compounds (prodrugs).
[0531] Pharmaceutical composition
[0532] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention as defined above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in association with a pharmaceutically acceptable excipient (eg, a pharmaceutically acceptable diluent or a pharmaceutically acceptable carrier).
[0533] The pharmaceutical composition preferably comprises an effective amount (more preferably a therapeutically effective amount) of a compound of formula (1) or (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
[0534] The pharmaceutical composition can be formulated for delivery, particularly selective delivery to macrophages.
[0535] For example, the pharmaceutical composition may comprise a compound of the invention as defined hereinbefore in the form of nanoparticles, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
[0536] In general, the compositions of the invention may be in a form suitable for oral use (e.g., as tablets (e.g., swallowable tablets), lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as finely divided powders or liquid aerosols), administration by insufflation (e.g., as finely divided powders) or for parenteral administration (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration or as suppositories for rectal administration).
[0537] The compositions of the present invention can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.
[0538] An effective amount of a compound of the invention for use in treatment (particularly a therapeutically effective amount) is an amount sufficient to treat or prevent, slow the progression of and / or reduce the symptoms associated with a DHCR24-mediated disorder mentioned herein.
[0539] The amount of active ingredient combined with one or more excipients to produce a single dosage form will necessarily vary depending on the individual being treated and the particular route of administration. For example, a formulation intended for oral administration to humans typically contains, for example, 0.5 mg to 0.5 g of active agent (more preferably 0.5 mg to 100 mg, e.g. 1 mg to 30 mg) compounded with a suitable and convenient amount of excipients, which may be from about 5% to about 98% by weight of the total composition.
[0540] According to known medical principles, the size of the dose of the compound of formula (1) or (10) for therapeutic or preventive purposes will naturally vary depending on the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration.
[0541] It should be noted that dosage and administration regimen may vary with the type and severity of the disease to be alleviated, and may include single or multiple doses of administration within a specific time period (several days or hours), i.e., QD (once a day), BID (twice a day), etc. It should also be understood that for any particular object or patient, a specific dosage regimen may need to be adjusted over time according to individual needs and the professional judgment of the person administering or supervising the administration of the pharmaceutical composition. For example, the dosage can be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include clinical effects, such as toxic effects and / or laboratory values. Therefore, the present application encompasses intra-patient dose escalation determined by those skilled in the art. The procedures and processes for determining appropriate dosage and administration regimen are well known in the relevant art and will be easily determined by the technician. Therefore, it will be easily understood and recognized by those of ordinary skill that the dosage ranges described herein are only exemplary and are not intended to limit the scope or practice of the pharmaceutical composition described herein.
[0542] In using the compound of the present invention for treatment or prevention purposes, if needed in divided doses, it will generally be administered so as to accept a daily dose of, for example, 0.1 mg / kg body weight to 75 mg / kg body weight. Generally speaking, when parenteral route is adopted, a lower dosage will be administered. Therefore, for example, for intravenous administration or intraperitoneal administration, a dosage of, for example, 0.1 mg / kg body weight to 30 mg / kg body weight will generally be used. Similarly, for administration by inhalation, a dosage of, for example, 0.05 mg / kg body weight to 25 mg / kg body weight will be used. Oral administration may also be suitable, particularly in tablet form. Generally speaking, a unit dosage form will contain about 0.5 mg to 0.5 g of the compound of the present invention.
[0543] Therapeutic uses and applications
[0544] In another aspect, the present invention provides a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for use in treatment and / or as a medicament. The treatment may be treatment of the human or animal body.
[0545] In another aspect, the present invention provides a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for use in treating or preventing a DHCR24-mediated disorder.
[0546] In another aspect, the present invention provides a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for use in treating or preventing non-alcoholic fatty liver disease (NASH). A compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein can be used to treat or prevent non-alcoholic fatty liver disease (NASH) without inducing hyperlipidemia and / or hypertriglyceridemia.
[0547] In another aspect, the present invention provides a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for treating or preventing atherosclerotic cardiovascular disease (asCVD). A compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein can be used to treat or prevent atherosclerotic cardiovascular disease (asCVD) without inducing hyperlipidemia and / or hypertriglyceridemia.
[0548] In another aspect, the present invention provides a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein, for use in treating or preventing multiple sclerosis (MS).
[0549] In another aspect, the present invention provides the use of a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in the preparation of a medicament for treating or preventing a DHCR24-mediated disorder.
[0550] In another aspect, the present invention provides the use of a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in the preparation of a medicament for treating or preventing non-alcoholic steatohepatitis (NASH), preferably without inducing hyperlipidemia and / or hypertriglyceridemia.
[0551] In another aspect, the present invention provides the use of a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in the preparation of a medicament for treating or preventing atherosclerotic cardiovascular disease (asCVD), preferably without inducing hyperlipidemia and / or hypertriglyceridemia.
[0552] In another aspect, the present invention provides the use of a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in the preparation of a medicament for treating or preventing multiple sclerosis (MS).
[0553] In another aspect, the present invention provides a method for treating or preventing a DHCR24-mediated disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein.
[0554] In another aspect, the present invention provides a method for treating or preventing non-alcoholic steatohepatitis (NASH) without inducing hyperlipidemia and / or hypertriglyceridemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein.
[0555] In another aspect, the present invention provides a method for treating or preventing atherosclerotic cardiovascular disease (asCVD) without inducing hyperlipidemia and / or hypertriglyceridemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein.
[0556] In another aspect, the present invention provides a method for treating or preventing multiple sclerosis (MS), the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition as defined herein.
[0557] Another aspect of the present invention provides a method for inhibiting DHCR24 activity in vivo or in vitro.
[0558] The in vivo or in vitro method comprises contacting a cell with a compound of formula (1) or formula (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition.
[0559] Alternatively, the in vivo method may comprise administering to a subject in need thereof a therapeutically effective amount of a compound of formula (1) or (10) as defined herein, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition.
[0560] In another aspect, the present invention provides a combination comprising a compound of formula (1) or formula (10), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and one or more additional therapeutic agents.
[0561] In each of the above aspects, the DHCR24-mediated disorder can be selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD), multiple sclerosis (MS), hepatocellular carcinoma (HCC), breast cancer, endometrial cancer, B-cell lymphoma, drug-resistant cancer and hepatitis C.
[0562] Additionally or as an alternative to the DHCR24-mediated condition defined above, in each of the above aspects, the DHCR24-mediated condition may be liver inflammation, liver fibrosis and / or liver damage. Preferably, the DHCR24-mediated condition is liver fibrosis and / or liver damage.
[0563] The breast cancer is preferably luminal breast cancer or HER2-positive breast cancer.
[0564] The drug-resistant cancer is preferably a methotrexate-resistant cancer.The cancer may be gestational trophoblastic neoplasia (GTN).
[0565] Preferably, the DHCR24-mediated condition is non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD) or multiple sclerosis (MS). The DHCR24-mediated condition is preferably non-alcoholic steatohepatitis (NASH). The DHCR24-mediated condition is preferably atherosclerotic cardiovascular disease (asCVD). The DHCR24-mediated condition is preferably multiple sclerosis (MS).
[0566] Nonalcoholic steatohepatitis (NASH) and atherosclerotic cardiovascular disease (asCVD) cause substantial morbidity and mortality. In fact, asCVD is the leading cause of death in Western countries. Both diseases are driven by lipids / cholesterol and inflammation. While asCVD is primarily treated with statins to lower cholesterol, effective drugs for NASH do not currently exist and NASH is primarily treated with lifestyle interventions. In addition to lipid-lowering approaches, both diseases would highly benefit from a concurrent anti-inflammatory approach.
[0567] By inhibiting the enzyme 24-dehydrocholesterol reductase (DHCR24), the final step of cholesterol de novo synthesis is mediated. This is the step where the enzyme converts sterols to cholesterol. DHCR24 inhibition not only reduces cholesterol synthesis, but also induces an increase in sterols, which are endogenous ligands for liver X receptor α (LXRα). Activation of LXRα leads to effective anti-inflammatory effects and inhibits the activation of macrophages. Synthetic LXRα ligands in the prior art induce lipogenesis through SREBP in hepatocytes, producing a large amount of hypertriglyceridemia (another risk factor for CVD). In contrast, the increase in sterols caused by the selective DHCR24 inhibitor compounds of the present invention activates LXRα without side effects, such as inducing hypertriglyceridemia.
[0568] It has been found that streptosteroids play a key role in resolving inflammation in demyelinating lesions in multiple sclerosis (see Nature Neuroscience, 2021, 24(1), pp.47-60). The increase in streptosteroids produced by selective DHCR24 inhibitor compounds can be used to treat or prevent (preferably treat) multiple sclerosis.
[0569] It has been shown that overexpression of DHCR24 is associated with poor clinical outcomes in patients with hepatocellular carcinoma (see British Journal of Cancer, 2000, 123, pp. 1673-1685). Therefore, DHCR24 inhibitors may be useful in preventing or treating HCC.
[0570] Cholesterol has been shown to be a risk factor for breast cancer. It has been shown that DHCR24 expression is higher in breast cancer compared to normal breast, especially in luminal and HER2-positive breast cancer tissues (see Cancer Sci., 2020, 111(10), pp.3653-3664). Therefore, compounds that inhibit DHCR24 can be used to treat or prevent breast cancer.
[0571] DHCR24 is also associated with urogenital tumors. It has been shown that DHCR24 is significantly elevated in patients with endometrial cancer (EC), and upregulation of DHCR24 is associated with advanced clinical stage, histological grade, vascular invasion, lymphatic metastasis, and decreased overall survival (see Scientific Reports, 2017, 7(1), pp.41404; DOI: 10.1038 / srep41404). Therefore, compounds that inhibit DHCR24 can be used to treat or prevent EC.
[0572] DHCR24 has been identified as a direct target of SOX9 (oncogenic stem cell regulator) in B-cell lymphoma. It has been shown that SOX9 can drive lymph node generation through DHCR24 and cholesterol biosynthesis pathways (see Blood, 2022, 139 (1), pp. 73-86). Therefore, compounds that inhibit DHCR24 can be used to treat or prevent B-cell lymphoma.
[0573] DHCR24 has been identified as a potential downstream effector of DPP4 (see Front. Oncol., 2 December 2021; https: / / doi.org / 10.3389 / fonc.2021.704024). Targeting DPP4 / DHCR24 signaling may help sensitize methotrexate-resistant cancers, particularly gestational trophoblastic tumors (GTNs).
[0574] It has been shown that hepatitis C virus (HCV) infection induces the expression of DHCR24 in human hepatocytes (see J. Hepatol., 2011, 55(3), pp. 512-521). Inhibition of DHCR24 can reduce HCV replication. Therefore, compounds that inhibit DHCR24 can be used to treat or prevent hepatitis C.
[0575] Route of administration
[0576] The compounds or pharmaceutical compositions of the invention may be administered to a subject by any convenient route of administration, whether systemically / peripherally or topically (ie, at the desired site of action).
[0577] Routes of administration include, but are not limited to: oral (e.g., by ingestion); buccal; sublingual; transdermal (including, for example, by patches, plasters, etc.); transmucosal (including, for example, by patches, plasters, etc.); intranasal (e.g., by nasal sprays); ocular (e.g., by eye drops); pulmonary (e.g., by use of, for example, inhalation or insufflation therapy via an aerosol, such as through the mouth or nose); rectal (e.g., by suppositories or enemas); vaginal (e.g., by vaginal suppositories); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, and intrasternal; by implantation of a reservoir or depot, for example, subcutaneous or intramuscular.
[0578] Combination therapy
[0579] The treatment defined hereinbefore may be used as a sole therapy or may involve the administration of one or more therapeutic agents in addition to a compound of formula (1) or formula (10).
[0580] The therapeutic agent may be a lipid-lowering agent, such as a statin, a PCSK9 inhibitor (e.g., Evolocumab, Alirocumab), or an NPC1L1 inhibitor (e.g., Ezetemibe), particularly when the DHCR24-mediated disorder is atherosclerotic cardiovascular disease (asCVD).
[0581] According to this aspect of the invention, a combination for treating or preventing a DHCR24-mediated disorder (particularly treating or preventing non-alcoholic steatohepatitis (NASH) or atherosclerotic cardiovascular disease (asCVD)) is provided, comprising a compound of formula (1) or (10) as defined above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and another therapeutic agent, such as a therapeutic agent for treating or preventing non-alcoholic steatohepatitis (NASH) or atherosclerotic cardiovascular disease (asCVD).
[0582] In this document, when the term "combination" is used, it should be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention, "combination" refers to simultaneous administration. In another aspect of the invention, "combination" refers to separate administration. In another aspect of the invention, "combination" refers to sequential administration. In the case of sequential or separate administration, delaying the administration of the second component should not result in a loss of the beneficial effects of the combination. In one embodiment, the combination refers to a combination product.
[0583] According to another aspect of the present invention, there is provided a combination comprising a compound of formula (1) or (10) as defined above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and a therapeutic agent such as those described above.
[0584] In one embodiment, a pharmaceutical composition is provided, comprising a compound of formula (1) or formula (10) as defined above, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and another therapeutic agent, in combination with a therapeutic agent such as those described above, in association with a pharmaceutically acceptable diluent or carrier.
[0585] Example
[0586] The following examples are provided to illustrate the invention and are not intended to limit the scope of the invention as described herein.
[0587] The compounds of the present invention can be prepared using synthetic techniques known in the art (as shown in the Examples herein).
[0588] Several methods for chemically synthesizing the compounds of this application are described herein. These and / or other known methods can be modified and / or adjusted in various ways to facilitate the synthesis of other compounds within the scope of this application and the claims. Such alternative methods and modifications should be understood to be within the spirit and scope of the application and the claims. Therefore, it should be understood that the methods set forth in the following description, schemes, and embodiments are intended to be used for illustrative purposes and should not be construed as limiting the scope of this disclosure.
[0589] Synthesis of compounds
[0590] Compounds were prepared from commercially available starting materials. The general reaction scheme shown in Scheme 1 illustrates a published synthesis of common / reactive key intermediates starting from commercially available ergosterol, which can be used to synthesize most of the compounds listed below.
[0591] Solution 1
[0592]
[0593] The compounds of Examples 1, 9 to 11, 16, 21, 25, 28, 29 were prepared as described in C. Müller et al., Eur. J. Med. Chem., 2017, 140, 305-320.
[0594] The compounds of Examples 2 to 8, 12, 14, 15, 17 to 20, 22 to 24, 26, 27 were prepared as described in Sandra Hemmers, “Seitenkettenfunktionalisierte Steroide als Inhibitoren der Ergosterol-undCholesterolbiosynthese”, PhD thesis, LMU Munich, 2012 (DOI: 10.5282 / edoc.15485).
[0595] The compound of Example 13 was prepared as described in D. Renard et al., Bioorg. Med. Chem., 2009, 17, 8123-8137.
[0596] Example 1
[0597]
[0598] Example 2
[0599]
[0600] Example 3
[0601]
[0602] Example 4
[0603]
[0604] Example 5
[0605]
[0606] Example 6
[0607]
[0608] Example 7
[0609]
[0610] Example 8
[0611]
[0612] Example 9
[0613]
[0614] Example 10
[0615]
[0616] Embodiment 11
[0617]
[0618] Example 12
[0619]
[0620] Example 13
[0621]
[0622] Embodiment 14
[0623]
[0624] Embodiment 15
[0625]
[0626] Example 16
[0627]
[0628] Embodiment 17
[0629]
[0630] Embodiment 18
[0631]
[0632] Embodiment 19
[0633]
[0634] Embodiment 20
[0635]
[0636] Embodiment 21
[0637]
[0638] Embodiment 22
[0639]
[0640] Embodiment 23
[0641]
[0642] Embodiment 24
[0643]
[0644] Embodiment 25
[0645]
[0646] Embodiment 26
[0647]
[0648] Embodiment 27
[0649]
[0650] Embodiment 28
[0651]
[0652] Embodiment 29
[0653]
[0654] Embodiment 30
[0655]
[0656] (3S,20R)-20-(Hydroxymethyl)-pregn-7-en-3-yl acetate (MiH-7)
[0657] (3S, 20S) -20- formyl pregnant -7- ene -3- base acetate (151mg, 0.405mmol) and p-toluenesulfonic acid (7.8mg, 0.041mmol) were loaded into a flame-dried Schlenk flask. After being dissolved in dry toluene (1mL) under a nitrogen atmosphere, piperidine (0.642mL, 6.5mmol) was added, and the solution was stirred at 70°C for 3 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (EtOAc) and washed three times with 0.1M HCl. The organic layer was dried using hydrophobic filter paper, and the solvent was removed in vacuo. The crude product was purified by flash column chromatography (flash column chromatography, FCC) (hexane / EtOAc 90:10) to produce 95mg (63%) of a white solid, which was directly reduced. Therefore, the previously obtained aldehyde (184 mg, 0.494 mmol) was dissolved in a 3:2 mixture of dry CHCl / MeOH in a flame-dried Schlenk flask under a nitrogen atmosphere. After the addition of sodium borohydride (18.9 mg, 0.5 mmol), the mixture was stirred at room temperature for 2 hours. The reaction was quenched with saturated NH4Cl solution and the aqueous layer was extracted with CHCl3 (3×3 mL). The combined organic layers were dried over a hydrophobic filter paper and the solvent was removed in vacuo. After purification using FCC (hexane / EtOAc 90:10->80:20), (3S, 20R)-20-(hydroxymethyl)-pregn-7-ene-3-yl acetate (65 mg, 0.17 mmol, 35%) was obtained as a colorless solid.
[0658] 1 H NMR (500MHz, CDCl3) δ5.16 (m, 1H, H-7), 4.69 (tt, 3 J H3-H2,H4 =11.3, 4.6Hz, 1H, H-3), 3.73(dd, 3 J H22-H22 =10.6, 3 J H22-H20 =3.6Hz, 1H, H-22), 3.49(dd, 3 J H22-H22 =10.6, 3 J H22-H20 =6.9Hz, 1H, H-22), 2.02 (s, 3H, CH3CO), 1.93-1.30 (m, 20H), 1.25 (tdz, J = 12.9, 4.2Hz, 1H), 1.17-1.09 (m, 1H, H-17), 0.96 (d, 3 J H21-H20=6.7Hz, 3H, H-21), 0.81 (s, 3H, H-19), 0.55 (s, 3H, H-18). 13 C NMR (126MHz, CDCl3) δ170.8(CH3CO), 139.3(C-8), 117.8(C-7), 73.6(C-3), 67.1(C-22), 55. 0(C-14), 52.6(C-C20), 49.3(C-9), 43.3(C-13), 40.2(C-5), 39.1(C-12), 38.4(C-17), 37.0 (C-1), 34.34 (C-10), 33.9 (C-11), 29.7 (C-6), 27.6 (C-2 or C-4), 27.4 (C-2 or C-4), 22.9 (C-15 or C-16), 21.6 (CH3CO), 21.6 (C-15 or C-16), 16.8 (C-21), 13.1 (C-19), 12.4 (C-18). HR-MS (EI): C 24 H 38 The calculated value of O3 is 374.2821 and the measured value is 374.2816.
[0659] (3S, 20R)-20-(Hydroxymethyl)-pregn-7-en-3-ol (MiH-8)
[0660] To a stirred solution of (3S,20R)-20-(hydroxymethyl)-pregn-7-en-3-yl acetate (65 mg, 0.174 mmol) in MeOH was added a solution of KCO (288 mg, 174 mmol) in water (2.35 mL). The mixture was heated to reflux for 2 hours, then cooled to room temperature and concentrated under reduced pressure. The precipitate was redissolved in EtOAc and the organic layer was washed twice each with saturated KHCO solution, water and brine. After filtering the organic layer through a hydrophobic filter paper to remove water, the solvent was removed in vacuo. After purification by FCC (hexane / EtOAc 70:30), (3S,20R)-20-(hydroxymethyl)-pregn-7-en-3-yl-alcohol (28 mg, 0.084 mmol, 48%) was obtained as a colorless to light gray solid.
[0661] 1H NMR (400MHz, DMSO-d6) δ5.14-5.08 (m, 1H, H-7), 4.45 (s, 1H, OH), 4.27 (s, 1H, OH), 3.54 (d, J=10.3Hz, 1H, H-22), 3.33 (s, 6H, Under H-3), 3.10 (t, J=8.9Hz, 1H, H-22), 1.91-0.93 (m, 27H), 0.85 (d, J=6.6Hz, 3H, H-21), 0.72 (s, 3H, H-19), 0.49 (s, 3H, H-18). 13 CNMR (101 MHz, DMSO-d6) δ 139.1 (C-8), 117.2 (C-7), 68.90 (C-3), 64.9 (C-22), 54.4 (C-14), 52.4 (C-17), 48.9 (C-9), 42.8 (C-13), 39.5 (C-5, in DMSO), 38.4 (C-12), 38.1(C-20), 37.9(CH2), 36.7(CH2), 33.8(C-10), 31.3(C-1), 29.3(CH2), 26.6(C H2), 22.4(CH2), 21.0(CH2), 16.7(C-21), 12.9(C-19), 12.1(C-18).HR-MS(EI): C 22 H 36 The calculated value of O2 is 332.2715 and the measured value is 332.2711.
[0662] Embodiment 31
[0663]
[0664] (3S, 20S)-20-(Hydroxymethyl)-pregn-7-en-3-ol (MiH-10)
[0665] Under nitrogen atmosphere, in a flame-dried Schlenk flask, lithium aluminum hydride (56.7 mg, 1.49 mmol) was dispersed in dry THF. The mixture was cooled to 0 ° C in an ice bath, and a solution of (3S, 20S)-20-formylpregn-7-ene-3-yl acetate (105 mg, 0.282 mmol) in THF (1 mL) was added dropwise. The mixture was stirred overnight while warming to room temperature. The reaction was quenched with water and the mixture was acidified with 1M HCl. The aqueous layer was extracted with EtOAc (3×3 mL) and the combined organic layers were filtered through a hydrophobic filter paper to remove water. After removing the solvent under reduced pressure, the crude product was subjected to FCC (hexane / EtOAc 1: 1). The diol (63 mg, 0.19 mmol, 67%) was obtained as a colorless solid.
[0666] 1 H NMR (400MHz, CDCl3) δ5.19-5.14 (m, 1H, H-7), 3.64 (dd, J=10.8, J=3.5Hz, 1H, H-22), 3.58 (dt, J=10.6, 4.5Hz, 1H, H-3), 3.39 (dd, J=10. 3, J=7.0Hz, 1H, H-22), 2.05-1.98 (m, 1H, H-6), 1.93-1.17 (m, 22H), 1.06 (d, J=6.6Hz, 3H, H-21), 0.80 (s, 3H, H-19), 0.56 (s, 3H, H-18). 13 C NMR (101MHz, CDCl3) δ139.5(C-8), 117.8(C-7), 71.2(C-3), 68.1(C-22), 54. 9(C-14), 52.5(C-17), 49.6(C-5), 43.6(C-13), 40.4(C-9), 39.6(C-6), 39.3( C-20), 38.1(C-2), 37.3(C-1), 34.4(C-10), 31.6(CH2), 29.8(CH2), 27.6(CH2 ), 23.2(CH2), 21.7(CH2), 17.0(C-21), 13.2(C-19), 12.1(C-18).HR-MS(EI):
[0667] C 22 H 36 The calculated value of O2 is 332.2715 and the measured value is 332.2710.
[0668] (3R,20S)-20-[(4-nitrobenzoyloxy)methyl]-pregn-7-en-3-yl 4-nitrobenzoate
[0669] Under nitrogen atmosphere, (3S, 20S)-20-(hydroxymethyl)-pregn-7-ene-3-ol (54 mg, 0.16 mmol), 4-nitrobenzoic acid (204 mg, 1.22 mmol) and triphenylphosphine (319 mg, 1.22 mmol) were dissolved in dry THF (1 mL), and the mixture was subsequently cooled to 0 ° C in an ice bath. Diisopropylazodicarboxylate (DIAD) (0.113 mL, 0.568 mmol) was added dropwise. The reactants were warmed to room temperature and stirred overnight, then quenched by adding saturated NH4Cl (2 mL). After the aqueous layer was extracted with DCM (3×3 mL), the combined organic extracts were filtered through a hydrophobic filter paper to remove water. The solvent was removed under reduced pressure and the crude product was subjected to FCC (hexane / EtOAc 80:20). (3R,20S)-20-[(4-nitrobenzoyloxy)methyl]-pregn-7-en-3-yl 4-nitrobenzoate (76 mg, 0.12 mmol, 74%) was obtained as a colorless solid.
[0670] 1 H NMR (500MHz, CDCl3) δ8.32-8.26 (m, 4H, aromatic), 8.23-8.18 (m, 4H, aromatic), 5.35 (t, J =2.8Hz, 1H, H-3), 5.24 (m, 1H, H-7), 4.41 (dd, J = 10.7, 3.5Hz, 1H, H-22), 4.10 (dd, J=10.7, 7.6Hz, 1H, H-22), 2.08 (dt, J=12.5, 3.7Hz, 1H, H-6), 2.00-1.24 (m, 22H), 1.15 (d, J=6.6Hz, 3H, H-21), 0.87 (s, 3H, H-19), 0.63 (s, 3H, H-18). 13C NMR (126 MHz, CDCl3) δ 165.0 (COO), 164.1 (COO), 150.7 (aromatic), 150.6 (aromatic), 139.3 (C-8), 136.6 (aromatic), 136.1 (aromatic), 130.8 (aromatic), 123.7 (aromatic), 123.7 (aromatic), 118.1 (C-7), 72.1 (C-3), 71.0 (C-22), 55.0 (C-14), 53.0 (C-17), 49.7(C-9), 43.9(C-13), 39.5(C-6), 36.6(C-20), 36.1(C-5), 34.7(C-10), 33.2(CH2), 32.6(C-4), 29.5( CH2), 27.7(CH2), 26.2(C-2), 23.2(CH2), 21.4(C-1), 17.6(C-21), 12.4(C-19), 12.1(C-18).HR-MS(EI):
[0671] C 36 H 42 The calculated value of N2O8 is 630.2941 and the measured value is 630.2932.
[0672] (3R, 20S)-20-(Hydroxymethyl)-pregn-7-en-3-ol (MiH-12)
[0673] (3R, 20S)-20-[(4-nitrobenzoyl)methyl]-pregn-7-en-3-yl 4-nitrobenzoate (80 mg, 0.13 mmol) was dissolved in THF (2 mL) and cooled to 0 ° C in an ice bath, 0.38 mL of 2M NaOH solution was slowly added, the mixture was warmed to room temperature and stirred overnight. The reaction mixture was diluted with DCM (5 mL) and the organic layer was washed three times with water, 1M HCl and brine. After filtering through a hydrophobic filter paper to remove water, the solvent was removed under reduced pressure. The crude product was subjected to FCC (hexane / EtOAc 70: 30) to obtain (3R, 20S)-20-(hydroxymethyl)-pregn-7-en-3-ol (36 mg, 0.11 mmol, 85%) as a colorless to light yellow solid.
[0674] 1 H NMR (500MHz, DMSO) δ5.13 (m, 1H, H-7), 4.28 (dd, 3 J H22-OH =5.7, 4.8Hz, 1H, OH), 4.20(d, 3 J H3-OH =3.2Hz, 1H, OH), 3.83(q, 3 JH3-H2 , J H3-H4 =2.9Hz, 1H, H-3), 3.42(s, 1H, H-22), 3.07(ddd, 3 J H17-H20 =10.3, 3 J H20-H22 =7.1, 3 J H20-H21 =5.8Hz, 1H, H-22), 1.99-1.09(m, 21H), 0.95(d, 3 J H21-H20 =6.5Hz, 3H, H-21), 0.71 (s, 3H, H-19), 0.50 (s, 3H, H-18). 13 C NMR (126MHz, DMSO) δ139.1(C-8), 117.5(C-7), 65.7(C-22), 64.0(C-3), 54.3( C-14), 52.2(C-17), 49.1(C-5), 43.1(C-13), 40.1(C-20), 38.9(C-6), 35.3(C -2), 34.3(C-10), 34.2(C-9), 31.7(C-1), 29.2(C-11), 28.5(C-12), 27.1(C-4 ), 22.7(CH2), 20.8(CH2), 17.2(C-20), 12.1(C-19), 11.9(C-18).HR-MS(EI):
[0675] C 22 H 36 The calculated value of O2 is 332.2715 and the measured value is 332.2711.
[0676] Embodiment 32
[0677]
[0678] (3S)-20-Formyl-20-methylpregn-7-en-3-yl acetate (MiH-6)
[0679] At room temperature, (3S, 20S) -20-formyl pregnant-7-ene-3-yl acetate (250mg, 0.671mmol) and KOtBu (753mg, 6.71mmol) were dissolved in dry DCM (10mL) under nitrogen atmosphere. When a white precipitate was formed, iodomethane (1.25mL, 20.1mmol) was added dropwise. The mixture was stirred for three hours and then quenched by adding saturated NH4Cl solution (5mL). The aqueous layer was extracted three times with DCM and the combined organic extracts were filtered through a hydrophobic filter paper to remove water. The solvent was removed under reduced pressure and the crude product was subjected to FCC (hexane / EtOAc 95:5). (3S) -20-formyl-20-methyl pregnant-7-ene-3-yl acetate (155mg, 0.401mmol, 59%) was obtained as a colorless solid.
[0680] 1 H NMR (400 MHz, CDCl3) δ 9.63 (s, 1H, CHO), 5.18-5.14 (m, 1H, H-7), 3.34 (s, 3H, H3CCOO), 3.12 (tt, J = 11.1, 4.4 Hz, 1H, H-3), 1.93-1.53 (m, 18H), 1.50-1.13 (m, 10H), 1.11 (s, 3H, H-21 or H-21'), 1.09 (s, 3H, H-21 or H-21'), 1.03 (td, J = 13.5, 3.4 Hz, 1H, H-1), 0.76 (s, 3H, H-19), 0.55 (s, 3H, H-18). 13 C NMR (101MHz, CDCl3) δ206.80 (CHO), 170.8 (H3CCOO), 138.8 (C-8), 118.5 (C-7), 79.7 (C-3), 5 7.5(C-17), 55.7(H3CCOO), 55.0(C-14), 49.5(C-9), 48.9(C-20), 44.2(C-13), 40.3(C-5), 39 .5 (C-12), 37.2 (C-1), 34.7 (C-10), 34.3 (CH2), 29.9 (CH2), 27.8 (CH2), 23.0 (C-21 or C-21'), 22.6 (CH2), 22.4 (CH2), 21.5 (CH2), 20.9 (C-21 or C-21'), 14.7 (C-18), 13.1 (C-19). HR-MS (EI):
[0681] C 25 H 38 The calculated value of O3 is 386.2821 and the measured value is 386.2826.
[0682] (3S)-20-Hydroxymethyl-20-methylpregn-7-en-3-yl acetate (MiH-9)
[0683] Under nitrogen atmosphere, (3S)-20-formyl-20-methylpregn-7-en-3-yl acetate (128 mg, 0.331 mmol) was dissolved in a 3:2 mixture of dry CHCl3 / MeOH in a flame-dried Schlenk flask. After the addition of sodium borohydride (12.7 mg, 0.335 mmol), stirring was continued at room temperature for 1 hour. The reaction was quenched with saturated NH4Cl solution (3 mL) and the aqueous layer was extracted with CHCl3 (3×3 mL). The combined organic extracts were dried using hydrophobic filter paper and the solvent was removed under reduced pressure. After purification using FCC (hexane / EtOAc 90:10->80:20), (3S)-20-hydroxymethyl-20-methylpregn-7-en-3-yl acetate (87 mg, 0.22 mmol, 67%) was obtained as a colorless solid.
[0684] 1 H NMR (500 MHz, CDCl3) δ 5.16 (dq, J = 4.6, 2.3 Hz, 1H, H-7), 3.35 (s, 3H, CH3CO), 3.40-3.31 (m, 2H, H-22), 3.12 (tt, J = 11.2, 4.4 Hz, 1H, H-3), 2.06-2.01 (m, 1H, H-9), 1.91-1.00 (m, 20H), 0.99 (s, 3H, H-21 or H-21 1 ), 0.90(s, 3H, H-21 or H-21 1 ), 0.78 (s, 3H, H-19), 0.62 (s, 3H, H-18). 13 C NMR (126 MHz, CDCl3) δ 139.4 (H3CCO), 118.1 (C-7), 79.7 (C-3), 77.4 (C-8), 72.8 (C-22), 55.7 (H3CCO), 55.5 (C-5), 55.4 (C-17), 49.5 (C-14), 44.4 (C-13), 40.3 (C-9), 40.0, 39.0 (C-20), 37.2, 34.7 (C-10), 34.4, 29.9, 27.9, 23.6 (C-21 or C-22). 1 ), 23.5(C-21 or C-21 1 ), 22.8(CH2), 22.6(CH2), 21.6(CH2), 14.6(C-19), 13.1(C-18).HR-MS(EI):
[0685] C 22 H 36 The calculated value of O2 is 388,2977, and the measured value is 388,2975.
[0686] (3S)-20-Hydroxymethyl-20-methylpregn-7-en-3-ol (MiH-13)
[0687] To a stirred solution of (3S)-20-hydroxymethyl-20-methylpregn-7-en-3-yl acetate (80 mg, 0.21 mmol) in MeOH (25 mL) was added a solution of KCO (342 mg, 2.06 mmol) in water (2.8 mL). The mixture was heated to reflux for 4 hours, then cooled to room temperature and concentrated under reduced pressure. The precipitate was redissolved in EtOAc, and the organic layer was washed successively with saturated KHCO solution (2×5 mL), water, and brine. After filtering the organic layer through a hydrophobic filter paper to remove water, the solvent was removed in vacuo. After purification by FCC (hexane / EtOAc 70:30), (3S)-20-hydroxymethyl-20-methylpregn-7-en-3-ol was obtained as a colorless solid (24 mg, 0.069 mmol, 33%).
[0688] 1 H NMR (500MHz, CDCl3) δ5.16 (m, 1H, H-7), 3.59 (tt, J=11.0, 4.5Hz, 1H, H-3), 3.35 (q, J=10.6Hz, 2H, H-22), 2.03 (ddd, J=12.3, 4.0, 2.6Hz, 1H, H-9), 1.86-1.04 (m, 22H), 0.99 (s, 3H, H-21 or H-21 1 ), 0.90(s, 3H, H-21 or H-21 1 ), 0.79 (s, 3H, H-19), 0.62 (s, 3H, H-18). 13 C NMR (126MHz, CDCl3) δ139.4(C-8), 118.1(C-7), 72.8(C-22), 71.2(C-3), 55.5(C-14), 55.4(C-17), 49.5(C-5), 44.4(C- 13), 40.4(C-9), 40.0(C-2), 39.0(C-20), 38.1(C-4), 37.3(C-6), 34.3(C-10), 31.6(C-1), 29.8(C-11), 23.6(C-21 or C-21 1 ), 23.5(C-21 or C-21 1), 22.8(C-15), 22.6(C-16), 21.6(C-12), 14.6(C-18), 13.2(C-19).HR-MS(EI):
[0689] C 23 H 38 The calculated value of O2 is 346.2872, and the measured value is 346.2876.
[0690] Embodiment 33
[0691]
[0692] (3S, 20S)-20-(3,4-dimethylpentyl-1-enyl)-pregnane-5,7,9-trien-3-ol (MiH-16)
[0693] To the solution of eosin Y (5015mg, 7.25mmol) in 95%EtOH (150mL) add concentrated H2SO4 (0.402mL, 7.25mmol). The white precipitate formed is removed from the solution by vacuum filtration, and nitrogen is passed through for 30 minutes. Ergosterol (5000mg, 12.6mmol) and 75mL THF are added in the dark. The 500mL round-bottomed flask equipped with the reaction mixture and stirring beads is placed in a box equipped with an LED band, which is fixed on a highly polished interior. The reaction mixture is vigorously stirred for 38 hours while being exposed to blue LED light. The colorless precipitate formed is filtered and washed with ice-cold EtOH, then dried in a vacuum, to obtain diergostertrienol (3510mg, 4.44mmol, 70%) as a colorless to light yellow solid, which is used for the next step without further purification. Under nitrogen atmosphere, add the above-mentioned solid (930mg, 1.18mmol) suspended in dry toluene to the 500mL round-bottom flask through flame drying equipped with boiling beads (boiling bead) and reflux condenser.By mixture heating to reflux and when all solids dissolve, dropwise add N, O-bis (trimethylsilyl) acetamide (0.632mL, 2.59mmol).Continue stirring 5.5 hours, then reaction mixture is cooled to room temperature, and desolventizes under reduced pressure.Add 30mL acetone to precipitate and be heated to reflux and continue 5 minutes.Form white precipitate after cooling, it is collected by filtration and dried in vacuum to obtain bis-TMS-bis-ergosterol (816mg, 0.872mmol, 74%) as crude product. After this, under nitrogen atmosphere, in the round-bottom flask equipped with reflux condenser and boiling beads, crude product (753mg, 0.805mmol) is dissolved in diethylene glycol monoethyl ether (40mL).Mixture is heated to reflux and continues 10 minutes, then quickly cooled to 100 ℃ and poured into the stirring mixture of ice and water containing a small amount of p-toluenesulfonic acid crystals.After 24 hours at-20 ℃, white precipitate is collected by filtration, and washed with ice-cold water.Recrystallization from MeOH obtains new ergosterol (neoergosterol) (401mg, 1.05mmol, 65%) as white powder.
[0694] 1H NMR (400MHz, CDCl3) δ6.90 (d, J=7.9Hz, 1H, H-6), 6.85 (d, J=7.8Hz, 1H, H-7), 5.30-5.18 (m, 2H , H-22, H-23), 4.17-4.07 (m, 1H, H-3), 3.10-3.02 (m, 1H, CH2), 2.82-2.72 (m, 2H, CH2), 2.70-2 .59(m, 4H, CH2), 2.27-2.19(m, 1H, CH2), 2.16-2.00(m, 4H, CH2, H-20), 1.97-1.77(m, 4H, CH2, H-24), 1.73-1.32 (m, 9H, CH2, H-17, H-25), 1.09 (d, J=6.6Hz, 3H, H-21), 0.97-0.90 (m, 3H, H-24 1 ), 0.84 (ddq, J=7.1, 4.5, 2.2, 1.8Hz, 6H, H-26, H-27), 0.60 (s, 3H, H-18). 13 C NMR (101MHz, CDCl3) δ138.1(C-9), 135.7(C-22), 134.2(C-8), 133.6(C-10), 132.2(C-23), 131.3(C-5), 127.0(C-6), 124.0(C-7), 67.3(C-3), 55.2(C-17), 52.0(C-14), 43.0(C-24), 4 1.9 (C-13), 40.7 (C-20), 39.1 (CH2), 37.0 (CH2), 33.3 (C-25), 31.8 (CH2), 29.3 (CH2), 25.3 (CH2), 24.8 (CH2), 24.3 (CH2), 21.2 (C-21), 20.1 (C-25 or C-26), 19.8 (C-25 or C-26), 17.8 (C-24 1 ), 11.4(C-18).HR-MS(EI):
[0695] C 27 H 40 The calculated value of O1 is 380.3079, and the measured value is 380.3079.
[0696] (3S,20S)-20-(Hydroxymethyl)-pregnane-5,7,9-trien-3-ol (MiH-17, Example 33)
[0697] Pyridine (0.191mL, 2.36mmol) and a small amount of Sudan III crystals were added to a solution of neoergosterol (180mg, 0.473mmol) in DCM (23mL) in a 100mL gas washing bottle equipped with stirring beads and glass frit. When nitrogen was passed through, the solution was cooled to -50°C. After that, ozone (60L / hour, 60W) was introduced through a glass frit until the solution color became light yellow. Nitrogen was introduced for 10 minutes, then methanol (3.6mL) was added, followed by sodium borohydride (179mg, 4.73mmol) in small portions. Stirring was continued while slowly warming to room temperature. The reaction was quenched by adding 0.1M HCl (10mL) and the water layer was extracted with DCM (3×10mL). The combined organic layer was washed with 0.1M HCl (3×15mL), and then filtered through a hydrophobic filter paper to remove water. The solvent was removed under reduced pressure. The crude product was subjected to FCC (hexanes / EtOAc 70:30->1:1) to give (3S,20S)-20-(hydroxymethyl)-pregna-5,7,9-trien-3-ol (80 mg, 0.25 mmol, 53%) as a colorless solid.
[0698] 1 H NMR (400MHz, DMSO) δ6.79 (d, J=7.8Hz, 1H, H-6), 6.72 (d, J=7.7Hz, 1H, H-7), 4.72 (d, J=3.8Hz, 1H, HO-C-3), 4.30 (t, J=5.3Hz, 1H, CH2-OH), 3.82 (tt, J=8.5, 3.7Hz , 1H, H-3), 3.48-3.41 (m, 1H, H-22), 3.13 (dt, J=10.2, 6.3Hz, 1H, H-22), 2.85 (dd , J=16.0, 4.7Hz, 1H, H-4)), 2.69-2.47 (m, 13H), 2.16 (dt, J=12.7, 4.7Hz, 1H, H-12 und CH2), 2.06-1.89 (m, 3H), 1.66-1.54 (m, 2H, H-12 und CH2), 1.51-1.29 (m, 4H, H-17, H-20 und CH2), 1.02 (d, J=6.4Hz, 3H, H-21), 0.51 (s, 3H, H-18). 13C NMR (101MHz, DMSO) δ136.7(C-9), 133.3(C-8), 133.1(C-10), 132.0(C-5) , 126.4(C-6), 123.1(C-7), 65.6(C-22), 65.1(C-3), 51.2(C-17), 51.0(C -14), 41.4(C-13), 39.0(C-20), 38.8(C-4), 36.3(C-12), 31.6(CH2), 28.0(CH2), 24.4(CH2), 24.0(2xCH2), 17.0(C-21), 11.0(C-18).HR-MS(EI):
[0699] C 21 H 30 The calculated value of O2 is 314.2246 and the measured value is 314.2237.
[0700] Embodiment 34
[0701]
[0702] (3S,20R)-20-(2-Formyloxyethyl)-pregn-7-en-3-yl acetate (MiH-58)
[0703] Under nitrogen atmosphere, (3S,20R)-20-(hydroxyethyl)-pregn-7-en-3-yl acetate (60 mg, 0.15 mmol) (prepared as described in Sandra Hemmers. "Seitenkettenfunktionalisierte Steroide als Inhibitoren der Ergosterol-undCholesterolbiosynthese", PhD thesis, LMU Munich, 2012, DOI: 10.5282 / edoc.15485) and DMAP (9.4 mg, 0.077 mmol) were dissolved in dry DCM (4 mL) in a flame-dried round-bottom flask equipped with a stirring bead. To the solution was added dropwise a solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (136 mg, 0.695 mmol) in dry DCM (3 mL) and formic acid (0.029 mL, 0.70 mmol). The mixture was stirred at room temperature for 6 days, then quenched with 1M HCl (4mL). The aqueous layer was extracted with DCM (3×3mL) and the combined organic extracts were washed with water and brine. Filtered through hydrophobic filter paper to remove water, then removed the solvent in vacuo. Purified by FCC (hexane / EtOAc 90: 10) to obtain (3S, 20R)-20-(hydroxyethyl)-pregn-7-ene-3-yl acetate (44mg, 0.11mmol, 68%) as a colorless solid.
[0704] 1H NMR (400MHz, CDCl3) δ8.05 (s, 1H, CHO), 5.15 (dd, J=5.2, 2.5Hz, 1H, H-7), 4.69 (tt , J=11.2, 4.6Hz, 1H, H-3), 4.24 (ddd, J=10.7, 7.8, 5.0Hz, 1H, H-23), 4.16 (dt, J=1 0.9, 7.6Hz, 1H, H-23), 2.02 (s, 3H, H3CCOO), 2.00 (t, J=3.6Hz, 1H, H-12), 1.97-1. 09 (m, 25H), 0.98 (d, J=6.7Hz, 3H, H-21), 0.81 (s, 3H, H-18), 0.54 (s, 3H, H-19).13C NMR (101MHz, CDCl3) δ170.83(H3CCOO), 161.38(CHO), 139.38(C-8), 117.70(C-7), 73.59(C-3), 62.4 0(C-23), 56.13(C-17), 55.08(C-14), 49.35(C-9), 43.58(C-13), 40.17(C-5), 39.60(C-12), 36.97(C -1), 34.55(C-22), 34.34(C-10), 33.93(C-4), 33.62(C-20), 29.66(C-6), 28.07(C-16), 27.63(C-2) , 23.04(C-15), 21.61(H3CCOO), 21.58(C-11), 18.93(C-21), 13.08(C-19), 11.95(C-18).HR-MS(E1):
[0705] C 26 H 40 The calculated value of O4 is 416.2927 and the measured value is 416.2919.
[0706] Embodiment 35
[0707]
[0708] (3S,20S)-20-(3,4-dimethylpent-1-en-yl)-pregn-5,7,9-trien-3-yl acetate (MiH-31)
[0709] Neoergosterol (1976 mg, 5.19 mmol) was added to a round-bottom flask containing acetic anhydride (41 mL) and pyridine (0.83 mL, 10 mmol). The mixture was heated to 120 ° C for two hours and then cooled to room temperature overnight. A white precipitate was formed, which was filtered and washed with ice-cold MeOH. After drying in a vacuum, neoergosterol acetate (1452 mg, 3.44 mmol, 66%) was obtained as a colorless solid.
[0710] 1 H NMR (400MHz, CDCl3) δ6.87 (q, J=7.9Hz, 2H, H-6, H-7), 5.31-5.20 (m, 2H, H-22, H-23), 5.15 (tdd, J=8.1, 6.2, 4. 2Hz, 1H, H-3), 3.09 (dd, J=16.3, 5.0Hz, 1H, H-4), 2.87 (dd, J=16.2, 7.7Hz, 1H, H-4), 2.67 (d, J=6.1Hz, 5H, H-14 und CH2), 2.23 (ddd, J=12.9, 6.7, 2.5Hz, 1H, CH2), 2.10 (ddd, J=15.9, 5.4, 4.0Hz, 2H, H-20 und CH2), 2.06 (s, 3H, H3CCOO), 1.98-1.84 (m, 3H, H-24 and CH2), 1.73-1.63 (m, 1H, CH2), 1.54-1.13 (m, 5H, H-17und CH2), 1.09 (d, J=6.6Hz, 3H, H-21), 0.94 (d, J=6.9Hz, 3H, H-24 1 ), 0.89-0.82 (m, 6H, H-27, H-26), 0.61 (s, 3H, H-18). 13C NMR (101MHz, CDCl3) δ171.0(H3CCOO), 138.1(C-9), 135.7(C-22), 134.2(C-8), 133.2(C-10), 1322( C-23), 130.8(C-5), 126.7(C-6), 124.0(C-7), 70.0(C-3), 55.2(C-17), 51.9(C-14), 43.0(C-24), 41 .9 (C-13), 40.7 (C-20), 37.0 (C-12), 35.2 (CH2), 33.3 (C-25), 29.3 (CH2), 28.2 (CH2), 25.2 (CH2), 24.3 (CH2), 24.3 (CH2), 21.6 (H3CCOO), 21.2 (C-21), 20.1 (C-26 or C-27), 19.8 (C-26 or C-27), 17.8 (C-24 1 ), 11.5(C-18).HR-MS(EI):
[0711] C 29 H 42 The calculated value of O2 is 422.3185, and the measured value is 362.3080 (-H3CCOOH).
[0712] (3S,20S)-20-Formylpregnane-5,7,9-trien-3-yl acetate (MiH-32)
[0713] Pyridine (2.0mL, 25mmol) and a small amount of Sudan III crystals are added to the solution of new ergosterol acetate (1700mg, 4.02mmol) in dry DCM equipped with a gas washing bottle of stirring beads and glass frit. The solution is cooled to -78 ° C using a dry ice-acetone bath, while nitrogen is passed through the solution using a glass frit. After this, ozone (60L / hour, 60W) is introduced by a glass frit until the solution color changes from light pink to light yellow. Again, nitrogen is passed through the solution, followed by addition of dimethyl sulfide (0.59mL, 8.0mmol) dissolved in MeOH (20mL) after 10 minutes. Stirring continued for another 30 minutes at -78 ° C, then the reaction mixture was warmed to room temperature. After removing the solvent under reduced pressure, the oily residue was dissolved in ethyl acetate (40mL) and washed with 5% KHSO4 solution (3 × 40mL). The organic layer is filtered through hydrophobic filter paper to remove water and remove the solvent in a vacuum. The crude product was subjected to FCC (hexane / EtOAc 90:10) to give (3S,20S)-20-formylpregna-5,7,9-trien-3-yl acetate (1090 mg, 3.08 mmol, 76%) as a colorless solid.
[0714] 1 H NMR (400MHz, CDCl3) δ9.64 (d, J=3.1Hz, 1H, CHO), 6.90 (d, J=7.9Hz, 1H, H-6), 6.85 (d, J=7.8Hz, 1H, H-7), 5.15 (dddd, J=9. 1, 7.9, 5.0, 3.1Hz, 1H, H-3), 3.09 (dd, J=16.3, 5.0Hz, 1H, H-4), 2.87 (dd, J=16.3, 7.7Hz, 1H, H-4), 2.77-2.60 (m, 5H, H-14 und CH2), 2.46 (dqd, J=10.0, 6.8, 3.1Hz, 1H, H-20), 2.24-2.08 (m, 4H, CH2), 2.06 (s, 3H, H3CCOO), 1.98-1.88 (m, 1H, H-2), 1.7 4(dt, J=14.5, 8.2Hz, 2H, H-17, CH2), 1.60 (ddd, J=10.9, 8.2, 4.1Hz, 2H, CH2), 1.21 (d, J=6.8Hz, 3H, H-21), 0.65 (s, 3H, H-18). 13 C NMR (101 MHz, CDCl3) δ 205.0 (CHO), 171.0 (H3CCOO), 137.3 (C-9), 133.9 (C-8), 133.3 (C-10), 131.2 (C-5), 126.9 (C-6 or C-7), 124.0 (C-6 or C-7), 69.9 (C-3), 51.2 (C-1), 50.2 ( C-17), 50.0(C-20), 42.6(C-13), 36.8(C-12), 35.2(C-4), 28.1(C-2), 27.9(CH2), 25. 0(CH2), 24.7(CH2), 24.3(CH2), 21.6(H3CCOO), 13.7(C-21), 11.7(C-18).HR-MS(EI):
[0715] C 23 H 30 The calculated value of O3 is 354.2195, and the measured value is 294.1978 (-H3CCOOH).
[0716] (3S,20S)-20-(Hydroxymethyl)-pregnane-5,7,9-trien-3-yl acetate (MiH-45)
[0717] Under nitrogen atmosphere, (3S,20S)-20-formylpregn-5,7,9-trien-3-yl acetate (140 mg, 0.395 mmol) was dissolved in a 3:2 mixture of dry CHCl3 / MeOH (4 mL) in a flame-dried Schlenk flask. After the addition of sodium borohydride (15 mg, 0.40 mmol), stirring was continued at room temperature for 1 hour. The reaction was quenched with saturated NH4Cl solution (3 mL) and the aqueous layer was extracted with CHCl3 (3×3 mL). The combined organic extracts were dried by filtration through hydrophobic filter paper and the solvent was removed in vacuo. After purification using FCC (hexane / EtOAc 70:30), (3S,20S)-20-(hydroxymethyl)-pregn-5,7,9-trien-3-yl acetate (130 mg, 0.365 mmol, 92%) was obtained as a colorless solid.
[0718] 1 H NMR (400MHz, CDCl3) δ6.87 (q, J=7.9Hz, 2H, H-6 und H-7), 5.15 (dddd, J=9.1, 8.0, 5.0, 3.1Hz, 1H, H-3), 3.70 (dd, J=10.5, 3.2Hz, 1H, H-22), 3.45 (dd, J=10.5, 6.7Hz, 1H, H-22), 3.09 (dd, J=16.3, 5.1Hz, 1H, H-4), 2.87 (dd, J=16.3, 7.7Hz, 1H, H-4), 2.75-2.62 (m, 5H, H-11, H-14, H-15, H16, H-17), 2.25 (ddd, J=13.2, 6.8, 2.5Hz, 1H, H-12), 2.16-2.08 (m, 3H, H-2, H-15, H-16), 2.06 (s, 3H, H3CCOO), 1.98-1.8 8 (m, 1H, H-2), 1.74-1.40 (m, 7H, H-12, H-14, H-15, H-16, H-17, H-20), 1.14 (d, J=6.6Hz, 3H, H-21), 0.62 (s, 3H, H-18). 13C NMR (101 MHz, CDCl3) δ 171.0 (H3CCOO), 137.9 (C-9), 134.2 (C-8), 133.2 (C-10), 130.9 (C-5), 126.8 (C-6), 124.0 (C-7), 70.0 (C-3), 68.1 (C-22), 51.6 (C-14 or C-17), 51.6 (C-14 or C-17) , 42.1 (C-13), 39.3 (C-20), 36.9 (C-12), 35.2 (C-4), 28.5 (C-1), 28.2 (C-2), 25.2 (C-11), 24.4 (C-15 or C-16), 24.3 (C-15 or C-16), 21.6 (H3CCOO), 17.0 (C-21), 11.3 (C-18). HR-MS (E1):
[0719] C 23 H 32 The calculated value of O3 is 356.2351, and the measured value is 338.2241 (-H2O).
[0720] (3S,20S)-20-[(2-fluoroacryloyloxy)methyl]-pregna-5,7,9-trien-3-yl acetate (MiH-46, Example 35)
[0721] Under nitrogen atmosphere, (3S, 20S)-20-(hydroxymethyl)-pregnane-5,7,9-triene-3-yl acetate (36 mg, 0.10 mmol), 2-fluoroacrylic acid (11.2 mg, 0.121 mmol) and DMAP (6.2 mg, 0.051 mmol) were dissolved in dry DCM (2 mL) in a flame-dried round-bottom flask equipped with stirring beads. A solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23.7 mg, 0.121 mmol) in dry DCM (1 mL) was added dropwise to the solution. The reaction was stirred for 48 hours and then quenched with 1M HCl (2 mL). The aqueous layer was extracted with DCM (3×3 mL) and the combined organic extracts were washed with water and brine. Water was removed by filtration through hydrophobic filter paper and the solvent was removed in vacuo. Purification by FCC (hexane / EtOAc 90:10) gave (3S,20S)-20-[(2-fluoroacryloyloxy)methyl]-pregna-5,7,9-trien-3-yl acetate (31.6 mg, 0.0737 mmol, 73%) as a colorless solid.
[0722] 1H NMR (500MHz, CDCl3) δ6.89 (d, J=7.8Hz, 1H, H-6), 6.85 (d, J=7.8Hz, 1H, H-7), 5.68 (dd, J=43.4, 3.2Hz, 1H, CFCH2), 5.33 (dd, J=13.0, 3.2Hz, 1H, CFCH2), 5.15 (dddd, J=9.2, 7.9, 5.0, 3.0Hz, 1H, H-3), 4.30 (dd, J=10.8, 3.5Hz, 1H, H-22), 4.03 (dd, J=10.8, 7.4Hz, 1H, H-22), 3.09 (dd, J=16.3 , 5.0Hz, 1H, H-4), 2.87 (dd, J=16.2, 7.7Hz, 1H, H-4), 2.74-2.63 (m, 5H, H-11, H-13), 2.25 (ddd, J=13.0, 7.1, 2.1Hz, 1H, H-12), 2.17-2.07 (m, 3H , H-1, H-15, H-16), 2.06 (s, 3H, H3CCOO), 1.98-1.87 (m, 2H, H-2), 1.75- 1.67(m, 1H, H-12), 1.62-1.52(m, 4H, H-1, H-15, H-16), 1.49-1.42(m, 1H H-17), 1.14 (d, J=6.6Hz, 3H, H-21), 0.63 (s, 3H, H-18). 13 C NMR (126MHz, CDCl3) δ171.0 (H3CCOO), 160.8 (d, J=36.3Hz, OOCCF), 153.6 (d, J=262.3Hz, OCOCF), 137.6 (C-9) , 134.0(C-8), 133.2(C-10), 131.0(C-5), 126.8(C-6), 124.0(C-7), 102.7(d, J=15.3Hz, CFCH2), 70.9(C-22) , 69.9(C-3), 51.9(C-17), 51.5(C-14), 42.3(C-13), 36.9(C-12), 36.4(C-20), 35.2(C-4), 28.5(C-16), 28.2(C-2), 25.1(C-11), 24.4(C-1 or C-15), 24.3(C-1 or C-15), 21.6(H3CCOO), 17.4(C-21), 11.3(C-18).HR-MS(EI):
[0723] C 26 H 33 The calculated value of FO4 is 428.2363, and the measured value is 368.2127 (-H3CCOOH).
[0724] Embodiment 36
[0725]
[0726] (3S,20RS)-20-(2-fluoro-1-hydroxyprop-2-enyl)-pregn-7-en-3-yl acetate (MiH-52)
[0727] A solution of tetra-n-butylammonium fluoride (TBAF) (1M in THF, 0.024 mL, 0.082 mmol) in THF (2 mL) was cooled to -78°C, and then a solution of fluorovinyldiphenylsilane (0.187 mL, 0.816 mmol) and (3S, 20S)-20-formyl-pregn-7-en-3-yl acetate (152 mg, 0.408 mmol) in dry THF (2 mL) was added dropwise. Stirring was continued at -78°C for one hour, and then the mixture was warmed to room temperature and stirred overnight. The reaction was then quenched by adding water, the two layers were separated and the aqueous layer was extracted with DCM (3×5 mL). The combined organic layers were dried by filtration through a hydrophobic filter paper, and the solvent was removed under reduced pressure. Purification by FCC (hexanes / EtOAc 90:10) gave (3S,20RS)-20-(2-fluoro-1-hydroxyprop-2-enyl)-pregnan-7-en-3-yl acetate (40 mg, 0.096 mmol, 23%) as a colorless solid as a mixture of epimers.
[0728] 1 H NMR (500MHz, CDCl3) δ5.20-5.14 (m, 1H, H-7), 4.76-4.53 (m, 3H, H-3, CFCH2), 4 .48(s,1H,H-22),4.29(s,1H,H-22),2.03(s,3H,H3CCOO),2.01-1.27(m,21H) , 1.14 (td, J=14.4, 13.9, 4.0Hz, 1H, H-4), 0.94 (d, J=6.8Hz, 2H, H-21), 0.86 (d , J=7.0Hz, 1H, H-21), 0.81 (s, 3H, H-19), 0.59 (s, 1H, H-18), 0.57 (s, 2H, H-18). 13C NMR (126MHz, CDCl3) δ 170.9 (H3CCOO), 166.8 (d, J = 259.0Hz, CF), 166.8 (d, J = 258.6Hz, CF), 139.3(C-8), 139.1(C-8), 117.9(C-7), 117.8(C-7), 89.8(d, J=16.9Hz, CFCH2), 8 9.6 (d, J=16.6Hz, CFCH2), 73.6 (C-3), 73.6 (C-3), 71.8 (d, J=34.8Hz, C-22), 70.8 (d, J =34.6Hz, C-22), 55.1(C-14), 55.0(C-14), 52.1(C-17), 51.7(C-17), 49.3(C-5), 43.5 (C-13), 43.3 (C-13), 40.2 (C-12), 39.5 (C-12), 39.2 (C-20), 38.2 (C-20), 37.1 (C-4), 37.0 (C-4), 34.4 (C-10), 33.9 (C-1 or C-2), 29.7 (C-6), 27.7 (C-11), 27.6 (C-11), 276 (C -1 or C-2), 23.0 (C-15 or C-16), 22.9 (C-15 or C-16), 21.6 (H3CCOO), 21.6 (C-15 or C-16), 13.1 (C-19), 13.1 (C-19), 12.3 (C-21), 12.0 (C-18), 12.0 (C-18), 11.8 (C-21). HR-MS (EI):
[0729] C 26 H 39 The calculated value of FO3 is 418.2883 and the measured value is 418.2877.
[0730] Embodiment 37
[0731]
[0732] (3S,20S)-20-[(2-Fluoro-N-methylacrylamide)methyl]-pregn-7-en-3-yl acetate
[0733] Under nitrogen atmosphere, the secondary amine from Example 13 (61 mg, 0.16 mmol), 2-fluoroacrylic acid (17.5 mg, 0.189 mmol) and DMAP (9.6 mg, 0.079 mmol) were dissolved in dry DCM (2 mL) in a flame-dried round-bottom flask equipped with boiling beads. A solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (36.9 mg, 0.189 mmol) in dry DCM (1 mL) was added dropwise to the solution. The reaction was stirred for 48 hours and then quenched with 1M HCl (2 mL). The aqueous layer was extracted with DCM (3×3 mL) and the combined organic extracts were washed with water (2×5 ml) and brine (5 ml). The combined organic extracts were dried by filtration through hydrophobic filter paper and the solvent was removed under reduced pressure. Purification by FCC (hexanes / EtOAc 70:30) gave (3S,20S)-20-[(2-fluoro-N-methylacrylamido)methyl]-pregnan-7-en-3-yl acetate (42.3 mg, 0.092 mmol, 58%) as a colorless solid.
[0734] 1 H NMR (500 MHz, CDCl3; mixture of rotamers) δ 5.31-5.03 (m, 3H, H-7, CFCH2), 4.69 (tt, J = 11.3, 4.6 Hz, 1H, H-3), 3.52-3.08 (m, 2H.H-22), 3.04 (s, 3H, NCH3), 2.92 (s, 3H, NCH3), 2 .02 (s, 4H, H3CCOO, under H-12), 1.97-1.17 (m, 19H), 1.13 (td, J=14.6, 13.9, 3.9Hz, 1 H, H-4), 0.90 (dd, J=13.2, 6.1Hz, 3H, H-21), 0.81 (s, 3H, H-19), 0.57 (s, 3H, H-18). 13C NMR (126 MHz, CDCl3; mixture of rotamers) δ 170.8 (H3CCOO), 163.2 (d, J = 29.0 Hz, COCF), 162.8 (d, J = 30.1 Hz, COCF), 159.4 (d, J = 23.3 Hz, CF), 157.2 (d, J = 22.2 Hz, CF), 139.2 (C-8), 139.1 (C-8), 118.0 (C-7), 117.8 (C-7), 99.2 (CFCH2), 99.1 (CFCH2), 73.6 (C-3), 55.7 (C-22), 54.8 (C-14), 54.6 (C-14), 53.8 (C-2 2), 49.3(C-5), 43.9(C-13), 40.2(C-9), 39.5(C-12), 37.0(C-4), 36.9(NC H3), 35.7(C-17), 35.2(C-20), 34.3(C-10), 34.0(NCH3), 33.9(C-11), 29. 6(C-6), 27.8(C-1 or C-2), 27.6(C-1 or C-2), 23.2(C-16), 21.6(H3CCOO), 21. 5(C-15), 16.8(C-21), 16.3(C-21), 13.1(C-19), 12.1(C-18).HR-MS(EI):
[0735] C 28 H 42 The calculated value of FNO3 is 459.3149 and the measured value is 459.3144.
[0736] Biological activity of compounds
[0737] Determination
[0738] A GC / MS-based screening assay for distal cholesterol biosynthesis inhibitors was used (see Müller et al., Nature Protocols, 2019, 14(8), pp. 2546-2570).
[0739] Two test concentrations (1 μM and 50 μM) were used. Compounds were dissolved in ethanol or DMSO and test stock solutions were prepared considering a final dilution of 1:100. Finally, 10 μL of the test stock solution was added to 990 μL of lipid-free medium containing 1% lipoprotein deficient serum (LPDS) without antibiotics. HL-60 cells (1×10 6cells) were incubated in 24-well plates in 1.0 mL of culture medium consisting of 990 μL of lipid-free medium, 1% LPDS, and 10 μL of the corresponding inhibitor solution.
[0740] After a 24-hour incubation period (conditions: 37°C in a humidified atmosphere containing 5% CO2), the contents of each well were transferred to a 2 mL plastic tube and the wells were washed with 750 μL of phosphate-buffered saline (PBS), and the washes were combined with the culture medium sample. Cells were collected by centrifugation at 540 × g for 5 minutes, the cells were washed once with 1 mL of ice-cold PBS, and centrifuged again under the same conditions. The samples were transferred to glass vials and 1 mL of 1 M NaOH was added to each vial and saponified at 70°C for 60 minutes.
[0741] After the sample is cooled to room temperature, it is transferred back in a 2mL plastic vial, and lipids are extracted by adding 100 μL internal standard solution (cholestane in MtBE, 10 μg / mL) and 650 μL MtBE. The pipe is vigorously shaken for 1 minute, and then centrifuged at 9200 × g for 5 minutes. Repeat extraction with 750 μL MtBE, and the organic extract is merged in a plastic tube containing 40mg dry sodium sulfate and 5mg Bondesil PSA. Subsequently, the sample is centrifuged at 9200 × g for 5 minutes. 1 milliliter of purified extract is transferred to an automatic sampler glass vial, and evaporated to dryness under a gentle stream of nitrogen.
[0742] 950 μL MtBE and 50 μL N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) and N-trimethylsilyl imidazole (TSIM) mixture (10: 1) were added to each vial. The silanization reaction was carried out at room temperature for 1 hour. The samples prepared in this way were analyzed on a GC-MS system equipped with helium as carrier gas and a 5-MS separation column. The sterol pattern obtained will qualitatively reveal the target enzyme in distal cholesterol biosynthesis (for details, see Müller et al., Nature Protocols, 2019, 14 (8), pp. 2546-2570).
[0743] For IC 50 To determine, the incorporation of labeled acetate into the target molecule cholesterol was assessed and the protocol was modified in the following way: 10 μL of sterile 2- 13 C-sodium acetate solution (6.25 mg / mL), followed by the addition of inhibitor solution, resulting in a final 13The C-acetate concentration was 62.5 μg / mL. After saponification, 3 × 25 μL aliquots were taken for protein determination using Bradford reagent. After treatment and silanization, GC-MS analysis allowed the determination of the protein content in cholesterol according to the formula given below: 13 C was incorporated for quantification. The percentage inhibition (see formula) relative to the untreated control sample (0% inhibition) was plotted against the logarithmic inhibitor concentration using Graph Pad Prism 4 (or higher). An underlying constant equal to 0 was set as a constraint using a sigmoidal dose-response model with different slopes. All samples were normalized to their protein. For each concentration, the percentage inhibition was determined in triplicate.
[0744]
[0745] The above formula is the calculation formula for inhibition percentage, where A S Indicates the sample area; A I.S.C. represents the internal standard control area; PC C Indicates the control protein content; A C Indicates the control area; A I.S.S. represents the internal standard sample area; and PC S Indicates the protein content of the sample.
[0746] result
[0747] The results are shown in Table 1.
[0748] Table 1
[0749]
[0750]
[0751] In vivo experiments using Example 11 (SH42)
[0752] Hemizygous APOE*3-Leiden (E3L) mice were crossed with homozygous human cholesterol ester transfer protein (CETP) transgenic mice to generate heterozygous E3L.CETP mice on a C57BL / 6J background [M. Westerterp et al., "Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice"; Arterioscler Thromb Vasc Biol 26, 2552-2559 (2006)]. Due to the phenotypic heterogeneity of E3L.CETP mice, non-responder mice were identified by fasting 4-hour lipid levels (i.e., total cholesterol levels <2 mM and triglyceride levels <2 mM) and excluded before special dietary treatment. Tularik (San Francisco, CA, US) provided LXRα-deficient mice (also on a C57BL / 6J background) generated by Deltagen using a gene targeting approach as described in [T. Plosch et al., "Abcg5 / Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice"; Am J Physiol Gastrointest Liver Physiol, 291, G414-423 (2006) (33)]. Mice were grouped and housed in individual ventilated cages at room temperature (22°C) and relative humidity of 40±5% and standard conditions of a 12-hour light / dark cycle (lights on at 7am; lights off at 7pm). All animals received humane care according to the standards outlined in the NIH "Guide for the Care and Use of Laboratory Animals". All animal procedures were performed in accordance with the guidelines of the European Parliament's Directive 2010 / 63 / EU on the protection of animals used for scientific purposes.
[0753] At 10 to 12 weeks of age, male E3L.CETP mice and LXRα-deficient mice were fed a high-fat, high-cholesterol diet (HFCD; Altromin, Germany) containing 60% (energy) fat and 1% (weight / weight) cholesterol and randomly divided into two groups and treated with the DHCR24 inhibitor compound of Example 11 [also referred to herein as SH42] (0.5 mg / mouse) by intraperitoneal injection three times a week. -1 ) or vehicle (saline containing 3.3% ethanol and 3.3% Cremophor EL). E3L.CETP mice were treated for 4 weeks (n=6 mice / group) and 8 weeks (n=8 mice / group) to evaluate the effects on hepatic immune cells by flow cytometric analysis and on hepatic steatosis by quantitative lipidomics analysis, respectively. LXRα-deficient mice were treated with SH42 (n=11 mice) or vehicle (n=10 mice) for 4 weeks to evaluate the effects on hepatic steatosis and immune cells. In the rescue experiment, male E3L.CETP mice were first fed with HFCD for 10 weeks and injected intraperitoneally with SH42 (0.5 mg / mouse) 3 times a week. -1 ) or vehicle (saline containing 3.3% ethanol and 3.3% Cremophor EL) for an additional 8 weeks.
[0754] Body weight was measured weekly. Body composition (i.e., adipose mass and lean mass; EchoMRI-100; EchoMRI, Houston, TX, USA) was assessed before and after the intervention. Food intake was determined during the treatment period.
[0755] result
[0756] Inhibition of DHCR24 by SH42 significantly increased hepatic sterol levels and improved hepatic steatosis
[0757] To evaluate the effect of DHCR24 inhibition on hepatic steatosis, E3L.CETP mice were fed HFCD and treated with vehicle or the synthetic DHCR24 inhibitor SH42 for an 8-week period. SH42 treatment did not affect food intake compared to the control group, while temporarily preventing HFCD-induced weight gain. After 8 weeks of treatment, the body weight and body composition (i.e., lean body mass and adipose body mass) of SH42-treated mice were comparable to those of the control group. In addition, the weights of multiple tissues (i.e., liver, white adipose tissue, kidney, heart, lung, spleen, and brown adipose tissue) did not change due to SH42 treatment. SH42 significantly increased hepatic streptosterol levels (10-fold, see Figure 3 A).
[0758] Hepatic steatosis was evaluated and scored by HE staining. Compared with the control treatment, SH42 treatment improved diet-induced hepatic steatosis, as evident by a significant decrease in hepatic steatosis score (-58%) and hepatic lipid area (-35%). Hepatic lipid profiles were analyzed by comprehensive lipidomics analysis. First, significant changes in lipid class composition were observed after SH42 treatment. Specifically, SH42 treatment resulted in a relative decrease in TAG (-21%) and DAG (-22%), accompanied by a relative increase in other lipid classes (including CER, PC, PE, and SM).
[0759] Most of the significantly altered lipid species were downregulated, and the majority of them were TAG. Consistently, SH42 tended to decrease triacylglyceride (TAG) (-39%; see Figure 3 B) and diacylglyceride (DAG) (-20%; see Figure 3 In addition, SH42 treatment reduced hepatic free fatty acid (FFA) (-16%; see Figure 3 D) and cholesterol esterase (CE) levels (-25%; see Figure 3 E). Despite a strong effect on hepatic lipid content, SH42 did not affect fasting plasma glucose, insulin, or homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores. In summary, inhibition of DHCR24 by SH42 significantly increased hepatic streptosterol levels, accompanied by improvements in diet-induced hepatic steatosis, without significant effects on body composition and glucose homeostasis.
[0760] Inhibition of DHCR24 by SH42 prevents Kupffer cell activation and reduces immune cell infiltration into the liver
[0761] By immunohistochemistry, DHCR24 inhibition affected liver inflammation in mice treated with SH42 or vehicle for 8 weeks. SH42 treatment significantly reduced liver F4 / 80 content (-29%) and the number of hepatic corona-like structures of macrophages surrounding dead hepatocytes (-79%), which is a prominent feature of NASH.
[0762] Flow cytometry of MACS-purified liver leukocytes revealed that 4 weeks of SH42 treatment tended to reduce total liver leukocytes (-37%; p = 0.09). A significant increase in total Kupffer cells (KC) was observed after SH42 treatment (+44%). Although SH42 did not significantly reduce MHCII + / CD11c + Activated KC, but MHCII - / CD11c - Resting KCs were significantly increased (+21%), indicating that KC activation was prevented. In addition, SH42 treatment reduced monocytes in both the liver (-79%) and blood (-43%; p=0.06) and reduced liver neutrophils (-50%) without affecting circulating neutrophils. In summary, these data indicate that SH42 treatment prevents KC activation, limits liver immune cell recruitment, and inhibits liver inflammation.
[0763] Inhibition of DHCR24 by SH42 does not increase circulating lipids
[0764] Consistent with the significant increase in hepatic streptococcin levels, SH42 also increased plasma streptococcin levels from undetectable levels (<0.5 μg mL -1 ) significantly increased to 3.1±0.4μg·mL -1 . Since synthetic LXR agonists generally induce lipogenesis and hypertriglyceridemia as unwanted effects, the effect of 8 weeks of SH42 treatment on circulating lipid levels was determined using quantitative integrated lipidomic analysis. Plasma lipidomic analysis revealed that SH42 treatment relatively reduced circulating CE while relatively increased lactosylceramide (LCER), phosphatidylcholine (PC), and phosphatidylethanolamine (PE). Regarding absolute lipid concentrations, SH42 did not affect plasma levels of total TAG and DAG, while significantly reducing plasma levels of FFA (-16%) and CE (-24%; p=0.08). These data indicate that inhibition of DHCR24 by SH42 increases plasma chain sterol levels and reduces FFA and CE levels, importantly without inducing hypertriglyceridemia.
[0765] Inhibition of DHCR24 via SH42 delays high-fat diet-induced liver inflammation, fibrosis, and injury
[0766] E3L.CETP mice were first fed HFCD for 10 weeks to establish NAFLD, and then treated with vehicle or SH42 for another 8 weeks while still receiving HFCD. SH42 treatment did not significantly affect total body weight or components. No differences were observed in liver weight and hepatic steatosis. SH42 treatment reduced liver inflammation (-89%) mainly by reducing liver crown-like structures, had no significant effect on F4 / 80 positive areas, and improved liver fibrosis, as demonstrated by reduced collagen content (-50%). In addition, SH42 treatment reduced plasma levels of liver injury markers (plasma alanine aminotransferase (ALT)) (-42%). These effects were accompanied by a robust increase in plasma chain sterol levels (>400 times). In summary, the inhibition of DHCR24 by SH42 delayed the progression of NAFLD / NASH induced by a high-fat diet from simple steatosis to late stages with severe liver inflammation, fibrosis and damage.
[0767] In vivo experiments using Example 11 (SH42) and Example 33 (MiH-17)
[0768] Experiments were performed to determine whether the compound of Example 33 (MIH17) increases brain and circulating sterol levels.
[0769] Mice received intraperitoneal injections of vehicle (saline containing 6% ethanol and 6% Cremophor EL; 5 μl / g mouse) and SH42 or MIH17 (50 μg / g mouse; 5 μl / g mouse) every day for three days. 24 hours after the last injection and after fasting for 4 hours (10 to 14 hours), mice were killed by CO2 inhalation (according to Zenya: 'Euthanasia with the use of the CO2 box (versie 4)'), after which blood was collected by cardiac puncture and organs were isolated. Chain sterol levels were determined by GC / MS as described below.
[0770] 5 μL of the internal standard mixture consisting of 1 mg / mL cholesterol, 20 μg / mL sterol-d6 and 20 μg / mL 25-OH-cholesterol-d6 was added to each sample. After hydrolysis in 80% (v / v) ethanol sodium hydroxide (1M), lipids were extracted twice in methyl-tert-butyl ether. After drying under nitrogen and derivatization with N-methyl-N-(trimethylsilyl) trifluoroformamide, sterols were analyzed on an Agilent GC-MS 5977B gas chromatograph coupled to a single quadrupole mass analyzer. In order to quantify sterols, the following ion traces were monitored: sterol-d6 and sterol were 333 and 327, respectively. Group comparison was performed based on the area ratio, and the sterol signal was corrected for its internal standard sterol d6.
[0771] The chain sterol signal detected in the sample is Figure 4 and Figure 5 It is shown in ( Figure 5 ; brain: p value 0.059; plasma: p value 0.017).
[0772] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
[0773] All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
[0774] Unless otherwise specified, the use of any and all examples or exemplary language (such as "for example") provided herein is intended only to better illustrate the present invention and is not intended to limit the scope of the present invention. No language in this specification should be construed as indicating that any non-illustrative element is essential to the practice of the present invention.
[0775] The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and / or enforceability of such patent documents.
[0776] This invention includes all modifications and equivalents of the subject matter recited in this appended paragraphs as permitted by applicable law.
Claims
1. A compound of formula (10), or a salt, solvate, hydrate or prodrug thereof, in: G is a fused ring system selected from the following: B is selected from: R 1 is selected from hydrogen and -C(=O)R 6 ; R 2 Selected from hydrogen and C 1-6 alkyl; R 3 A group selected from the group represented by formula (2), -[C(R 7 )2] n -X, -CH=CR 6 R 7 , -CR 7 =NN(R 6 )2, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups; n is an integer from 1 to 6; W is selected from O and NR 6 ; Y is selected from hydrogen and C2 alkenyl, wherein the C2 alkenyl is optionally substituted with one or more halogens; X is selected from halogen, -OH, -SH, -OZ, -SZ, -SSZ, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy is substituted with one or more groups; Each R 4 are independently selected from hydrogen and C 1-6 alkyl; R 5 Selected from hydrogen and C 1-6 alkyl; Each R 6 are independently selected from hydrogen and C 1-6 alkyl; Each R 7 Independently selected from H, C 1-6 Alkyl and C 2-6 alkenyl, wherein the C 1-6 Alkyl and C 2-6 The alkenyl group is optionally substituted with one or more halogens; Z is selected from C 6-10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the C 6-10 Aryl, 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl are optionally selected from -OH, halogen, -CN, -NH2, -NO2, C 1-6 Alkyl and C 1-6 substituted with one or more alkoxy groups; and wherein the prodrug is an ester, amide, hydrazone or disulfide of the compound of formula (10); and Wherein the compound is not one of the following:
2. The compound according to claim 1, or a salt, solvate, hydrate or prodrug thereof, wherein G is:
3. The compound according to claim 1 or claim 2, or a salt, solvate, hydrate or prodrug thereof, wherein R 5 is selected from hydrogen, methyl and ethyl.
4. The compound according to any one of claims 1 to 3, or a salt, solvate, hydrate or prodrug thereof, wherein each R 4 are independently selected from hydrogen, methyl and ethyl.
5. The compound according to any one of claims 1 to 4, or a salt, solvate, hydrate or prodrug thereof, wherein B is selected from:
6. The compound according to any one of claims 1 to 5, or a salt, solvate, hydrate or prodrug thereof, wherein R 2 It's hydrogen.
7. The compound according to any one of claims 1 to 6, or a salt, solvate, hydrate or prodrug thereof, wherein R 3 is a group represented by formula (2):
8. The compound according to claim 7, or a salt, solvate, hydrate or prodrug thereof, wherein each R 6 are independently selected from hydrogen, methyl and ethyl.
9. The compound according to any one of claims 1 to 6, or a salt, solvate, hydrate or prodrug thereof, wherein R 3 For -[C(R 7 )2] n -X.
10. The compound according to claim 9, or a salt, solvate, hydrate or prodrug thereof, wherein X is selected from halogen and -OH.
11. The compound according to claim 9, or a salt, solvate, hydrate or prodrug thereof, wherein X is -SH.
12. The compound according to claim 9, or a salt, solvate, hydrate or prodrug thereof, wherein X is -OZ, -SZ or -SSZ, and Z is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocycloalkyl, wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
13. The compound according to claim 9, or a salt, solvate, hydrate or prodrug thereof, wherein X is a 5- to 10-membered heteroaryl group.
14. The compound according to any one of claims 1 to 6, or a salt, solvate, hydrate or prodrug thereof, wherein R 3 -CH=CR 6 R 7 .
15. The compound according to claim 14, or a salt, solvate, hydrate or prodrug thereof, wherein said R 6 For H.
16. The compound according to claim 14 or claim 15, or a salt, solvate, hydrate or prodrug thereof, wherein R 7 Selected from hydrogen, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 2-6 Alkenyl and halo-C 2-6 Alkenyl.
17. The compound according to any one of claims 1 to 6, or a salt, solvate, hydrate or prodrug thereof, wherein R 3 For-CR 7 =NN(R 6 )2.
18. The compound according to any one of claims 1 to 6, or a salt, solvate, hydrate or prodrug thereof, wherein R 3 is selected from 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl, preferably wherein the 5- to 10-membered heteroaryl and 5- to 10-membered heterocycloalkyl each contain at least one nitrogen atom.
19. The compound according to claim 1, which is selected from:
20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable excipient.
21. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 20, for use in therapy and / or as a medicament.
22. A compound of formula (10) according to any one of claims 1 to 19, or a salt, solvate, hydrate or prodrug thereof, for use in treating or preventing a DHCR24-mediated disorder, wherein the DHCR24-mediated disorder is selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD), multiple sclerosis, hepatocellular carcinoma, breast cancer, endometrial cancer, B-cell lymphoma, drug-resistant cancer and hepatitis C.
23. The compound of the formula: It is used for treating or preventing a DHCR24-mediated disorder, wherein the DHCR24-mediated disorder is selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD), multiple sclerosis, hepatocellular carcinoma, breast cancer, endometrial cancer, B-cell lymphoma, drug-resistant cancer and hepatitis C.
24. The compound of the formula: It is used for treating or preventing a DHCR24-mediated disorder, wherein the DHCR24-mediated disorder is selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD), multiple sclerosis, hepatocellular carcinoma, breast cancer, endometrial cancer, B-cell lymphoma, drug-resistant cancer and hepatitis C, preferably multiple sclerosis.
25. The compound for use according to any one of claims 22 to 24, wherein the DHCR24-mediated disorder is selected from non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD) and multiple sclerosis.
26. The compound for use according to claim 25 for treating or preventing non-alcoholic steatohepatitis (NASH) or atherosclerotic cardiovascular disease (asCVD) without inducing hyperlipidemia and / or hypertriglyceridemia.
27. A compound, or a salt, solvate, hydrate or prodrug thereof, for use in treating or preventing a DHCR24-mediated disorder, wherein the DHCR24-mediated disorder is liver inflammation, liver fibrosis and / or liver damage, wherein the compound, its salt, solvate, hydrate or prodrug is as defined in any one of claims 1 to 19, 23 or 24.
Citation Information
Cited By
Application of DHCR24 protein acetylation in treatment and diagnosis of liver cancer
CN119438587A
Application of DHCR24 protein acetylation in the treatment and diagnosis of liver cancer
CN119438587B
